

**DATE 15 SEPTEMBER 2015**

**CURRICULUM VITAE**

**David E. Kandzari, MD**  
**Director, Interventional Cardiology**  
**Chief Scientific Officer**  
**Piedmont Heart Institute**  
**Atlanta, Georgia**

**Home Address:**

(b) (6)  
(b) (6)  
(b) (6)  
(b) (6)

**Work Address:**

Suite 300  
Piedmont Heart Institute  
275 Collier Road  
Atlanta, Georgia 30309  
Tel : +404 605 5526  
Fax : +404 720 0911  
Email : david.kandzari@piedmont.org

**Current and Prior Appointments**

Director, Interventional Cardiology  
Director, Interventional Cardiology Research  
Piedmont Heart Institute  
September 2010-present

Chief Scientific Officer  
Piedmont Heart Institute  
December 2010-present

Committee Member, Circulatory Systems Devices Panel  
United States Food and Drug Administration  
March 2009-present

Medical Officer, Medical Devices Fellowship Program  
Center for Devices and Radiological Health, United States Food and Drug Administration  
May 2008-January 2009 (Special Government Employee status March 2009-present)

Director, Interventional Cardiology Research  
Scripps Clinic, La Jolla, California  
August 2008-September 2010

Chief Medical Officer  
Cordis Corporation, a Johnson & Johnson Company  
December 2006-May 2008

Chief Medical Officer  
Conor Medical Systems  
March 2007-May 2008

John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences  
Assistant Professor of Medicine, Division of Cardiology  
Assistant Professor of Molecular Genetics and Microbiology  
Duke Clinical Research Institute, Duke University Medical Center, Durham, North  
Carolina  
July 2002- December 2006

### **Education and Training**

Duke University School of Medicine, Durham, North Carolina  
General and Interventional Cardiology Fellow 1998-2002

The Johns Hopkins University School of Medicine, Baltimore, Maryland  
Osler Service Medical Internship and Residency 1995-1998

Duke University School of Medicine, Durham, North Carolina  
M.D. 1995  
Rank: 1/105

Duke University, Durham, North Carolina  
B.A. Zoology 1991, B.A. Germanic Languages 1991; Magna cum laude

### **Certification and Licensure**

Diplomate, American Board of Internal Medicine, Internal Medicine, 1998

Licensure, State of North Carolina Medical Board 1998-2009; License 99-00559

Licensure, State of Texas Medical Board 2008; License N1357

Licensure, State of California Medical Board 2008; License C53376

Licensure, State of Georgia Medical Board 2010; License 064993

Diplomate, American Board of Internal Medicine, Cardiology Subspecialty, 2003, 2014

Diplomate, American Board of Internal Medicine, Interventional Cardiology  
Subspecialty, 2005

### **Refereed Publications**

1. Burr D, Schaffler M, Yang K, Lukoschek M, Kandzari DE, Sivaneri N, Blaha J, Radin E. Effects of altered strain environments on bone tissue kinetics. *Bone* 1989;10:215-221.
2. Heldman AW, Kandzari DE, Tucker RW, Crawford LE, Fearon ER, Koblan KS, Goldschmidt-Clermont PJ. EJ-Ras inhibits phospholipase C gamma 1 but not actin polymerization induced by platelet-derived growth factor-BB via phosphatidylinositol 3-kinase. *Circ Research* 1996;78:312-321.
3. Kandzari DE, Warner J, O'Laughlin M, Harrison JK. Percutaneous stenting of right pulmonary artery in fibrosing mediastinitis. *Catheterization and Cardiovasc Intervent* 2000;49:321-4.
4. Kandzari DE, Lam LC, Clapp-Channing N, Mark DB, Califf RM, Jollis JG. End-stage coronary artery disease: appropriate endpoints for trials of novel therapies. *Am Heart J* 2001;142:843-851.
5. Kandzari DE, Harrison JK, Behar VS. An anomalous left coronary artery originating from the pulmonary artery in a 72-year-old woman: diagnosis by color flow myocardial blush and coronary arteriography. *J Invas Cardiol* 2002;14:96-99.
6. Kandzari DE, Roe MT. Integrating GP IIb/IIIa Inhibition into treatment strategies for acute ST-elevation myocardial infarction. *J Invas Cardiol* 2002;14:565-574.
7. Kong DF, Hasselblad V, Kandzari DE, Newby KL, Califf RM. Seeking the optimal aspirin dose in acute coronary syndromes. *Am J Cardiol* 2002;90:622-625.
8. Kandzari DE, Sketch MH Jr., Goldberg S, et al. for the SCORES Trial Investigators. Clinical outcomes with a self-expanding nitinol stent in saphenous vein grafts: the Stent Comparative REStenosis (SCORES) Registry. *Am Heart J* 2002.
9. Kandzari DE, Zidar JP, Behar VS. The VB-1 catheter: a novel catheter for peripheral arterial revascularization. *Cathet Cardiovasc Intervent* 2003;59:514-517.

10. Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng JE, Kandzari DE, Topol EJ, Califf RM. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. *Am J Cardiol* 2003;92:651-655.
11. Kandzari DE. Catheter-based revascularization of the hepatic artery to treat coronary steal from a gastroepiploic artery bypass graft. *J Invas Cardiol* 2003;15:233-236.
12. Kandzari DE, Labinaz M, Cantor WJ, et al. Reduction of Myocardial Ischemic Injury Following Coronary Intervention (the MC-1 to Eliminate Necrosis and Damage Trial). *Am J Cardiol* 2003;92:660-664.
13. Kandzari DE, Tcheng JE, Cohen DJ, et al. Feasibility and implications of an early discharge strategy after percutaneous intervention with abciximab in acute myocardial infarction (the CADILLAC trial). *Am J Cardiol* 2003;92:779-784.
14. Tcheng JE, Kandzari DE, Grines CL, et al. for the CADILLAC Investigators. Abciximab treatment in primary angioplasty during acute myocardial infarction: final results of the CADILLAC trial. *Circulation* 2003;108:1316-1323.
15. Newby LK, Bhapkar MV, White HD, Moliterno DJ, Allen LaPointe NM, Kandzari DE, Verheugt FWA, Kramer JM, MD, Paul W. Armstrong, MD, Robert M. Califf, MD, for the SYMPHONY and 2<sup>nd</sup> SYMPHONY Investigators. Aspirin use post-acute coronary syndromes: intolerance, bleeding, and discontinuation. *J Thrombosis Thrombolysis* 2003;16:119-128.
16. Kandzari DE, Chu A, Brodie BR, et al. Feasibility of endovascular cooling as an adjunct to primary PCI: results of the LOWTEMP pilot study. *Am J Cardiol* 2004;92:779-784.
17. Kandzari DE, Granger CB, Simoons MS, Califf RM, White HD, Weaver WD, Gore J, Longstreth W, Sime J, Stebbins A, Lee K, Topol EJ for the GUSTO-I Investigators. Risk factors for stroke following thrombolytic therapy: case control study from the GUSTO-I trial. *Am J Cardiol* 2004;93:458-461.
18. Kandzari DE, Hasselblad V, Tcheng JE, Stone GW, Califf RM, Kastrati A, Neumann, FJ, Brener SJ, Montalescot G, Kong DF, Harrington RA. Improved clinical outcomes with abciximab therapy in acute myocardial infarction: a systematic overview of randomized clinical trials. *Am Heart J* 2004;147:457-462.
19. Quinn MJ, Aronow HD, Califf RM, Bhatt DL, Sapp S, Kleiman NS, Harrington RA, Kong DF, Kandzari DE, Topol EJ. Evidence for enhanced efficacy of discharge aspirin doses  $\geq 150$  mg after an acute coronary syndrome. *J Am Coll Cardiol* 2004;43:972-978.

20. Kandzari DE, Tchong JE, Grines CL, et al. Influence of admission and discharge aspirin use on survival after primary angioplasty for acute myocardial infarction. *Am J Cardiol* 2004;94:1029-1033.
21. Kandzari DE, Mehilli J, Schühlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Schömig A, Kastrati A, Berger PB, for the Intracoronary Stenting and Antithrombotic Regimen–Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators. Influence of treatment duration with a 600 mg dose of clopidogrel prior to percutaneous coronary revascularization. *J Am Coll Cardiol* 2004;44:2133-2166.
22. Kandzari DE, Roe MT, Chen AY, Lytle B, Pollack CV, Harrington RA, Ohman EM, Gibler WB, Peterson ED. Influence of clinical trial enrollment on the quality of care and outcomes for patients with non–ST-segment elevation acute coronary syndromes. *Am Heart J* 2005;149:474-481.
23. Waters RE, Kandzari DE, Phillips HR, Crawford LE, Sketch MH. Late thrombosis following treatment of in-stent restenosis with drug-eluting stents after discontinuation of antiplatelet therapy. *Cathet Cardiovasc Intervent* 2005;65:520-524.
24. Halabi AR, Kandzari DE. The thrill is gone: catheter-based exclusion of a posttraumatic arteriovenous fistula with a covered stent graft. *Cathet Cardiovasc Intervent* 2005;66:27-33.
25. Sorajja P, Gersh BJ, MB, Costantini C, McLaughlin MG, Zimetbaum P, Cox DA, MD, Garcia E, Tchong JE, Mehran R, Lansky AJ, Kandzari DE, Grines CL, Stone GW. Relative prognostic utility of ST-segment recovery and myocardial blush after primary percutaneous coronary intervention in acute myocardial infarction. *Eur Heart J* 2005;26:667-674.
26. Kandzari DE, Roe MT, Milford-Beland S, Ohman EM, Chen AY, Lytle BL, Cohen DJ, Smith SC, Harrington RA, Gibler WB, Peterson ED. Frequency, patterns and predictors of drug eluting stent utilization in patients with high-risk non-ST-segment elevation acute coronary syndromes: insights from the CRUSADE quality improvement initiative. *Am J Cardiol* 2005;96:750-755.
27. Stone GW, Colombo A, Teirstein PS, Moses JW, Leon MB, Reifart NJ, Mintz GS, Hoyer A, Cox DA, Baim DS, Strauss BH, Selmon M, Moussa I, Suzuki T, Tamai H, Katoh O, Mitsudo K, Grube E, Cannon LA, Kandzari DE, Reisman M, Schwartz RS, Bailey S, Dangas G, Mehran R, Abizaid A, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: Procedural techniques, devices, and results. *Cathet Cardiovasc Intervent* 2005;66:217-236.
28. Stone GW, Kandzari DE, Mehran R, Colombo A, Schwartz R, Bailey S, Moussa I, Teirstein PS, Dangas G, Baim DS, Selmon M, Strauss B, Tamai H, Suzuki T,

- Mitsudo K, Katoh O, Cox DA, Hoye A, Mintz GS, Grube E, Cannon L, Reifart NJ, Abizaid A, Moses JW, Leon MB, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: Part I. *Circulation* 2005;112:2364-2372.
29. Stone GW, Reifart NJ, Moussa I, Hoye A, Cox DA, Colombo A, Baim DS, Teirstein PS, Strauss BH, Selmon M, Mintz GS, Katoh O, Mitsudo K, Suzuki T, Tamai H, Grube E, Cannon L, Kandzari DE, Reisman M, Schwartz R, Bailey S, Dangas G, Mehran R, Abizaid A, Moses JW, Leon MB, Serruys PW. Percutaneous recanalization of chronically occluded coronary arteries: a consensus document: Part II. *Circulation* 2005;112:2530-2537.
  30. Kandzari DE, Tchong JE, Gersh BJ, Cox DA, Stuckey T, Turco M, Mehran R, Garcia E, Zimetbaum P, McGlaughlin MG, Lansky AJ, Costantini CO, Grines CL, Stone GW, for the CADILLAC Investigators. Relationship between infarct artery location, epicardial flow, and myocardial perfusion following primary percutaneous revascularization in acute myocardial infarction *Am Heart J* 2006;
  31. Kandzari DE, Kiesz RS, Allie D, Walker C, Fail P, Ramaiah VG, Cardenas J, Vale J, Chopra A, Gammon RG. Procedural and clinical outcomes for a novel method of catheter-based plaque excision in critical limb ischemia. *J Endovasc Ther* 2006;13:12-22.
  32. Kandzari DE, Tuttle RH, Zidar JP, Jollis JG. Influence of stenting on long-term outcomes among patients undergoing percutaneous coronary revascularization in clinical practice: 7-year follow-up from the Duke Database for Cardiovascular Disease *Am J Cardiol* 2006;97:1467-1472.
  33. Patel MR, Albert TSE, Kandzari DE, Honeycutt E, Shaw LK, Sketch MH, Elliott M, Judd R, Kim RJ. Clinical outcomes following cardiac magnetic resonance imaging early after percutaneous revascularization for acute myocardial infarction with drug-eluting and bare metal stents. *Radiology* 2006;240:674-680.
  34. Kandzari DE, Tuttle RH, Zidar JP, Jollis JG. Temporal Trends in Target Vessel Revascularization in Clinical Practice: Long-term Outcomes Following Coronary Stenting from the Duke Database for Cardiovascular Disease. *J Invas Cardiol* 2006;18:398-402.
  35. Rao S, Honeycutt E, Kandzari DE. Clinical outcomes with drug-eluting stents following atheroablation therapies. *J Invas Cardiol* 2006;18:393-396.
  36. Eisenstein E, Anstrom KJ, Kong DF, Shaw LK, Tuttle RH, Mark DB, Kramer JM, Harrington RA, Matchar DB, Kandzari DE, Peterson ED, Schulman KA, Califf RM. Clopidogrel use and long-term outcomes after drug-eluting stent implantation. *JAMA* 2007;10;297:159-168.

37. Kandzari DE, Leon MB, Popma JJ, et al. for the ENDEAVOR III Investigators. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. *J Am Coll Cardiol* 2006;48:2440-2447.
38. Ramaiah V, Gammon R, Kiesz S, Cardenas J, Runyon JP, Fail P, Walker C, Allie DE, Chamberlin J, Solis M, Garcia L, Kandzari D; TALON Registry. Midterm outcomes from the TALON Registry: treating peripherals with SilverHawk: outcomes collection. *J Endovasc Ther.* 2006;13:592-602.
39. Ikeno F, Braden GA, Kineda H, Hongo Y, Hinohara T, Yeung AC, Simpson JB, Kandzari DE. Mechanism of luminal gain with plaque excision in atherosclerotic coronary and peripheral arteries: assesment by histology and intravascular ultrasound. *J Interven Cardiol* 2007;20:107-113.
40. Tardif JC, Carrier M, Kandzari DE, Emery R, Cote R, Heinonen T, Zettler M, Hasselblad V, Guertin MC, Harrington RA. Effects of pyridoxal-5=phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery. Results of the MEND-CABG randomized study. *J Thorac Cardiovasc Surg* 2007;133:1604-1611.
41. Grossman PM, Mendelsohn F, Henry TD, Hermiller JB, Litt M, Saucedo JF, Weiss RJ, Kandzari DE, Kleiman N, Anderson RD, Gottlieb D, Karlsberg R, Snell J, Rocha-Singh K. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. *Am Heart J.* 2007 May;153(5):874-80.
42. Ellis SG, Kandzari D, Kereiakes DJ, Pichard A, Huber K, Resnic F, Yakubov S, Callahan K, Borgman M, Cohen SA. Utility of sirolimus-eluting Cypher stents to reduce 12-month target vessel revascularization in saphenous vein graft stenosis: results of a multi-center 350-patient case control study. *J Invas Cardiol* 2007;19:404-409.
43. Miyazawa A, Ako A, Hongo Y, Hur SH, Tsujino I, Courtney BK, Hassan AHM, Kandzari DE, Honda Y, Fitzgerald PJ, for the ENDEAVOR III Investigators. Comparison of vascular response to zotarolimus-eluting stent versus sirolimus-eluting stent: intravascular ultrasound results from ENDEAVOR III. *Am Heart J* 2007;155:108-113.
44. Pocock SJ, Lansky AJ, Mehran R, Popma JJ, Fahy MP, Na Y, Dangas G, Moses JW, Kandzari DE, Ellis SG, Leon MB, Stone GW. Angiographic surrogate endpoints in drug-eluting stent trials: a systematic evaluation based on individual patient data from eleven randomized controlled trials. *J Am Coll Cardiol* 2008;51:23-32.

45. (b) (4) Kandzari DE, (b) (4)  
*In Press*
46. Carrier M, Emery R, Kandzari DE, Harrington R, Guertin MC, Tardif JC. Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial. *J Cardiovasc Surg* 2008;49(2):249-253.
47. Mayor M, Kandzari DE, Malik AZ, Minor R, Deshpande M, Strauss WE, Maloney TH, Baim DS, O'Neill W. One-year outcomes in diabetic patients from the TAXUS Express<sup>2</sup> stent vs Cypher stent: What's Your Real-World Experience? (TC-WYRE) Registry. *Am J Cardiol* 2009;103:930-936.
48. Popma JJ, Tiroch K, Almonacid A, Cohen S, Kandzari DE, Barajas O, Leon MB. Stent fracture late following sirolimus-eluting stent implantation: a qualitative and quantitative angiographic analysis. *Am J Cardiol* 2009;103:923-929.
49. Price MP, Teirstein PS, Berger PB, Tanguay JF, Angiolillo D, Kandzari DE, Cannon CP, Topol EJ. Evaluation of individualized anti-platelet therapy after drug eluting stent implantation in patients with high residual platelet reactivity on clopidogrel: design and rationale of the GRAVITAS trial. *Am Heart J* 2009;157:818-824.
50. Kandzari DE, Rao S, Moses JW, Dzavik V, Strauss B, Kutryk MJ, Simonton CA, Garg J, Lokhnygina, Mancini GBJ, Yeoh E, Buller CE for the ACROSS/TOSCA-4 Investigators. Clinical and angiographic outcomes with sirolimus-eluting stents in total coronary occlusions: ACROSS/TOSCA-4 trial. *J Am Coll Cardiol Interv* 2009;2:97-106.
51. Price MJ, Nayak KR, Barker CM, Kandzari DE, Teirstein PS. Predictors of heightened platelet reactivity despite dual-antiplatelet therapy in patients undergoing percutaneous coronary intervention. *Am J Cardio* 2009;103:1339-1343.
52. (b) (4) Kandzari DE. (b) (4)  
*Submitted*
53. Leon MB, Kandzari DE, Eisenstein E, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS, Popma JJ, for the ENDEAVOR IV Investigators. Late safety, efficacy, and cost



- effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with *de novo* coronary lesions: two-year follow-up from the ENDEAVOR IV trial. *J Am Coll Cardiol Interv* 2009;2:1208-1218.
54. Rao S, Cohen MG, Kandzari DE, Bertrand O, Gilchrist IC. The transradial approach to percutaneous coronary intervention: historical perspective, current concepts, and future directions. *J Am Coll Cardiol* 2010;55:2187-2195.
  55. (b) (4) Kandzari DE,  
(b) (4)  
*Submitted*
  56. Waseda K, Miyazawa A, Ako J, Hasegawa T, Tsujino I, Sakurai R, Yock PG, Honda Y, Kandzari DE, Leon MB, Fitzgerald PJ. Intravascular ultrasound results from the ENDEAVOR IV trial: comparison between zotarolimus-eluting stent and paclitaxel-eluting stent. *J Am Coll Cardiol Interv* 2009;2:779-784.
  57. Kirtane AJ, Patel R, O'Shaughnessy C, Overlie P, McLaurin B, Solomon S, Mauri L, Fitzgerald P, Popma JJ, Kandzari DE, Leon MB. Clinical and angiographic outcomes in diabetics from the ENDEAVOR IV trial: randomized comparison of zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. *J Am Coll Cardiol Interv* 2009;2:967-76.
  58. Kandzari DE, Colombo A, Park SJ, Tommaso CL, Ellis SG, Guzman LA, Teirstein PS, Tamburino C, Ormiston J, Stone GW, MD, Dangas GD, Popma JJ, Bass TA, on behalf of the American College of Cardiology Interventional Scientific Council. Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards. *J Am Coll Cardiol* 2009;54:1576-1588.
  59. Eisenstein EL, Leon MB, Kandzari DE, Mauri L, Edwards R, Kong DF, Cowper PA, Anstrom KJ. Long-term clinical and economic analysis of the Endeavor zotarolimus-eluting stent versus the Cypher sirolimus-eluting stent: three-year results from the ENDEAVOR III trial. *J Am Coll Cardiol Interv* 2009; 2:1199-1207.
  60. Nayak KR, Mehta HS, Price MJ, Russo RJ, Stinis CT, Moses JW, Mehran R, Leon MB, Kandzari DE, Teirstein PS. A novel technique for ultra-low contrast administration during angiography or intervention. *Cathet Cardiovasc Intervent* 2010;75:1076-1083.
  61. Lee MD, Yang T, Kandzari DE, Tobis JM, Liao H, Mahmud E. Comparison by meta-analysis of drug-eluting stents with bare metal stents for saphenous vein graft intervention. *Am J Cardiol* 2010;105:1076-1082.

62. Kandzari DE, Farb A, Boam AB. Percutaneous Coronary Intervention in Perspective: Drug-Eluting Stents as a Model for Regulatory Review. *Circ Cardiovasc Intervent* 2009;2:574-579.
63. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen B, MD, Kirtane A, Fitzgerald PJ, Kandzari DE, for the ENDEAVOR IV Investigators. A randomized comparison of the ENDEAVOR zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in *de novo* native coronary lesions: 12-month outcomes from the ENDEAVOR IV trial. *J Am Coll Cardiol* 2010;55:543-554.
64. Brown RA, Williams M, Barker CM, Mauri L, Meredith IT, Fajadet J, Wijns W, Leon MB, Kandzari DE. Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results. *Cathet Cardiovasc Intervent* 2010
65. Yang Y, Kandzari DE, Gao Z, Xu B, Chen J, Qiao S, Li J, Qin X, Yao M, Wu Y, Yuan J, Chen J, Liu H, Dai J, Chen T, Li W, Gao R. Transradial versus transfemoral method of percutaneous coronary revascularization for unprotected left main coronary artery disease: comparison of procedural and late-term outcomes. *J Am Coll Cardiol Interv* 2010;3:1045-1042.
66. Barker CM, Murray SS, Teirstein PS, Kandzari DE, Topol EJ, Price MJ. Pilot study of the antiplatelet effect of increased clopidogrel maintenance dosing and its relationship to CYP2C19 polymorphism status in patients with high on-treatment reactivity. *J Am Coll Cardiol Interv* 2010;3:1001-1007.
67. Kandzari DE, Zankar A, Teirstein PS, Brilakis E, Banerjee S, Price M, Stinis C, Hudson P, Dahle T, Eng M, Brown R, Ferguson A, Addo TA, Popma JJ. Clinical outcomes following predilation with a novel 1.25 mm diameter angioplasty catheter. *Cathet Cardiovasc Intervent* 2011;77:510-514.
68. Saeed B, Kandzari DE, Agostoni P, Lombardi WL, Rangan BV, Banerjee S, Brilakis ES. Use of drug-eluting stents for chronic total occlusions: a systematic review and meta- analysis. *Cathet Cardiovasc Intervent* 2011;77:315-332.
69. Lee MS, Bokhoor P, Park SJ, Kim YH, Stone GW, Sheiban I, Biondi-Zoccai G, Sillano D, Tobis J, Kandzari DE. Unprotected left main coronary disease and acute myocardial infarction: a contemporary review and argument for percutaneous coronary intervention. *J Am Coll Cardiol Interv* 2010 2010;3:791-795.
70. Leon MB, Nikolsky E, Cutlip DE, Mauri L, Liberman H, Wilson H, Patterson J, Moses J, Kandzari DE, for the ENDEAVOR IV Investigators. Improved late

- clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with *de novo* coronary lesions: three-year follow-up from the randomized ENDEAVOR IV trial. *J Am Coll Cardiol Interv* 2010;3:1043-1050.
71. Mauri L, Massaro JM, Jiang S, Meredith I, Wijns W, Fajadet J, Kandzari DE, Leon MB, Cutlip DE, Thompson KP. Long-term clinical outcomes with zotarolimus-eluting coronary stents versus bare metal coronary stents. *J Am Coll Cardiol Interv* 2010;3:1240-1249.
  72. Ormiston JA, Devroey F, Webster MWI, Kandzari DE. The Petal Dedicated Bifurcation Stent. *Eurointervention* 2010. *Eurointervention* 2010;6.
  73. Lee MS, Stone GW, Park SJ, Teirstein PS, Moses JW, Colombo A, Kandzari DE. Percutaneous coronary intervention of unprotected left main coronary artery disease: procedural strategies and technical considerations. *Cathet Cardiovasc Intervent* *In press*; July 25 2011 DOI:1002/ccd.22689.
  74. Erlinge D, Gotberg M, Grines C, Dixon S, Baran K, Kandzari DE, Olivecrona GK. A pooled analysis of the effect of endovascular cooling on infarct size in patients with ST-elevation myocardial infarction. *EuroIntervention*. 2012 Nov 20. doi:pii: 20110718-02.
  75. Lee MS, Yang T, Kandzari DE, Mahmud E, Liao H, Kirtane A. Late-term outcomes in patients treated with drug-eluting and bare metal stents for treatment of transplant coronary artery disease. *Cathet Cardiovasc Intervent* 2012;80:533-538.
  76. Price MJ, Berger PB, Teirstein PS, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ, for the GRAVITAS Investigators. Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. The GRAVITAS Randomized Trial. *JAMA* 2011;305:1097-1105.
  77. Lee MS, Park SJ, Kandzari DE, Kirtane A, Fearon W, Brilakis E, Vermeersch P, Kim, YH, Waksman R, Mehilla J, Mauri L, Stone GW. Saphenous vein graft intervention. State of the art 2011. *J Am Coll Cardiol Interv* 2011;4:831-843.
  78. Kandzari DE, Barker CS, Leon MB, Mehran R. Dual antiplatelet therapy duration and clinical outcomes following treatment with zotarolimus-eluting stents. *J Am Coll Cardiol Interv* 2011;4:1119–1128.
  79. Kandzari DE, Mauri L, Popma JJ, Turco MA, Gurbel PA, Fitzgerald PJ, Leon MB. Late-Term Clinical Outcomes With Zotarolimus- and Sirolimus-Eluting Stents: 5-Year Follow-Up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System

- Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). *J Am Coll Cardiol Interv* 2011;4:543-550.
80. Karpaliotis D, Lembo N, Kalynych A, Carlson H, Lombardi WL, Anderson C, Rinehart S, Kirkland B, Chambless PA, Shemwell K, Qian Z, Voros S, Kandzari DE. Development of a high-volume, multiple-operator program for percutaneous chronic total coronary occlusion revascularization: procedural, clinical and cost-utilization outcomes. *Catheter Cardiovasc Interv* 2013 Apr 11. doi: 10.1002/ccd.24387.
  81. Kandzari DE, Ormiston JA. Revascularization for Unprotected Left Main Coronary Artery Disease: An Evolution in Clinical Decision Making. *Curr Cardiol Reports* 2011;13:424-431.
  82. Vavalle JP, Stevens SR, MS, Hassinger N, Cohen MG, Arnold A, Kandzari DE, Aguirre FV, MD, Gretler DD, Alexander JH. The Kinetics of Integrilin Limited by Obesity: A multicenter randomized pharmacokinetic and pharmacodynamic clinical trial. *Am Heart J* 2011; 162:996-1002.
  83. Kandzari, DE. Biodegradable polymer and permanent polymer drug-eluting stents: at the crossroads of evidence and expectation. *Future Medicine* 2012;4:147-150.
  84. Kereiakes DJ, Popma JJ, Cannon LA, Kandzari DE, Kimmelstiel CD, Meredith IA, Teirstein PS, Verheye S, Allocco DJ, Dawkins KD, Stone GW. Longitudinal stent deformation: quantitative coronary angiographic analysis from the PERSEUS and PLATINUM randomized controlled clinical trials. *Eurointervention* 2012; published online ahead of print March 25, 2012.
  85. Lee MS, Cheng R, Kandzari DE, Kirtane A. Long-term outcomes of heart transplantation recipients with transplant coronary artery disease who develop in-stent restenosis after percutaneous coronary Intervention. *Am J Cardiol* 2012;109:1729-1732.
  86. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack J, MD, Katzen Leon MB, Massaro J, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend R, Bakris G. Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPPLICITY Hypertension-3 Trial. *Clinical Cardiology* 2012. Published online ahead of print May 9 2012, DOI: 10.1002/clc.22008.
  87. Karpaliotis D, Lembo NJ, Brilakis ES, Kandzari DE. Percutaneous chronic total occlusion revascularization: program development, resource utilization and economic outcomes. *Intervent Cardiol Clin* 2012;1:391-395.
  88. Karpaliotis D, Michael T, Brilakis ES, Lembo N, Kalynych A, Carlson H,

- Banerjee S, Lombardi WL, Kandzari DE. Retrograde coronary chronic total occlusion revascularization: procedural and in-hospital outcomes from a multicenter registry in the United States. *Cathet Cardiovasc Intervent* 2012. *In press*
89. Brilakis ES, Grantham JA, Rinfret S, Wyman RM, Burke NM, Karpaliotis D, Lembo N, Pershad A, Kandzari DE, Buller CE, DeMartini T, Lombardi WL, Thompson CA. A percutaneous treatment algorithm for crossing coronary chronic total occlusions. *J Am Coll Cardiol Interv* 2012;5:367-379.
  90. Karpaliotis, D, Michael T, Brilakis ES, Lembo NJ, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Retrograde Coronary Chronic Total Occlusion Revascularization: Procedural and In-Hospital Procedural Outcomes from a Multicenter Registry in the United States. *J Am Coll Cardiol Interv* 2012;5:1273-1279.
  91. Rogers JH, Goldstein I, Kandzari DE, Köhler T, Stinis C, O'Connell K, Foss J, Woodson Z, Dolan M, Rocha-Singh K. Zotarolimus-Eluting Peripheral Stents for the Treatment of Erectile Dysfunction in Subjects with Suboptimal Response to Phosphodiesterase-5 Inhibitors. *J Am Coll Cardiol* 2012;60:2618-2627.
  92. Kosmidou I, Dan D, Karpaliotis D, Kandzari DE. Inadvertent Transarterial Lead Placement in the Left Ventricle and Aortic Cusp: Percutaneous Extraction with Carotid Embolic Protection and Stent Graft Placement. *Indian Pacing Electrophysiol J.* 2012;12(6):269-273.
  93. Bagur R, Bernier M, Kandzari DE, Karpaliotis D, Lembo NJ, Rinfret S. A Novel Application of Contrast Echocardiography to Exclude Active Coronary Perforation Bleeding in Patients With Pericardial Effusion. *Cathet Cardiovasc Intervent* 2013;82:221-229.
  94. Gao Z, Xu B, Yang YJ, Kandzari DE, Yan HB, Chen JL, Qiao SB, Wu YJ, Qin XW, Yao M, Yuan JQ, Liu HB, Chen J, Dai J, Chen T, Teng SY, Gao RL. Clinical and angiographic correlates of left ventricular dysfunction in patients with three vessel coronary disease. *Chin Med J* 2012;125:4221-4225.
  95. Park KW, MD, Kang SH, Velders MA, Shin DH, Hahn S, Lim WH, Yang HM, Lee HY, Van Boven AJ, MD, Hofma SH, Kang HJ, MD, Koo BK, Oh BH, Park YB, Kandzari DE, Kim HS. Safety and efficacy of everolimus- versus sirolimus-eluting stents: a meta-analysis of 11 randomized controlled trials and 3 observational studies. *Am Heart J* 2013;165(2):241-250.
  96. Kandzari DE, Leon MB, Meredith I, Fajadet J, Wijns W, Mauri L. Final 5-Year Outcomes from the Endeavor Zotarolimus-Eluting Stent Clinical Trial Program: Comparison of Safety and Efficacy with First Generation Drug-Eluting and Bare

- Metal Stents. J Am Coll Cardiol Interv 2013;6:504-512.
97. Kirtane A, Leon MB, Kandzari DE. The "final" five-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv. J Am Coll Cardiol Interv. 2013;6:325-333.
  98. Kandzari DE, Teirstein PS, Kereiakes D, Cannon LA, Hearne SE, Kuo HC, Ying SW, Cheong WF, Popma JJ. Procedural Effectiveness of a Novel 1.20 mm Diameter Angioplasty Catheter: Clinical and Angiographic Outcomes. Interv Cardiol. 2013 Apr;26(2):131-136.
  99. Karmaliotis D, Michael TT, Brilakis ES, Fuh E, Mogabgab PV, Kirkland BL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Coronary chronic total occlusion revascularization: procedural outcomes from a multicenter United States registry. Am J Cardiol 2013;112:488-492.
  100. Vardi M, Burke DA, Bangalore S, Pencina MJ, Mauri L, Kandzari DE, Leon MB, Cutlip DE. Long Term Efficacy and Safety of Zotarolimus Eluting Stent in Patients with Diabetes Mellitus: Pooled 5-year Results of the ENDEAVOR III and IV Trials. Circ Cardiovascular Intervent 2013;82:1031-1038.
  101. Park KW, Kang J, Kang SH, Ahn HS, Lee HY, Kang HJ, Koo BK, Chae IH, Youn TJ, Oh BH, Park YB, Kandzari DE, Kim HS. Usefulness of the SYNTAX and Clinical SYNTAX Scores in Predicting Clinical Outcome After Unrestricted Use of Sirolimus-and Everolimus-Eluting Stents. Circ J. 2013;77(12):2912-21.
  102. Yu M, Xu B, Wu Y, Yan H, Chen J, Qian J, Mu C, Hu F, Yang W, Qiao S, Yang Y, Kandzari DE, Gao RL. First Report of a Novel Polymer-Free Dual-Drug Eluting Stent in *De Novo* Coronary Artery Disease: Results of the First in Human BICARE Trial. Cathet Cardiovasc Intervent 2013;DOI: 10.1002/ccd.25129
  103. Navarese EP, Tandjug K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, Kereiakes D, Waksman R, Mauri L, Meridith I, Fin A, Kubica J, Di Pasquale G, Von Birgelen C, Kedhi E. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ 2013;347:f6530. doi: 10.1136/bmj.f6530.
  104. Ormiston J, Webster, MB, Stewart J, Vrolix M, Whitbourn R, Donohoe D, Knappe C, Lansky A, Attizzani GF, Fitzgerald P, Kandzari DE, Wijns W. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES With Sirolimus and a Bioabsorbable Polymer for the Treatment of Patients With De Novo Lesion in the

- Native Coronary Arteries). *J Am Coll Cardiol Intv* 2013  
doi.org/10.1016/j.jcin.2013.05.013
105. Park KW, Kang J, Kang SH, Ahn HS, Kang HJ, Koo BK, Chae IH, MD, Youn TJ, Oh BH, Park YB, Kandzari DE, Kim HS. The impact of residual coronary lesions on clinical outcomes after percutaneous coronary intervention: residual SYNTAX score after PCI in patients from the EXCELLENT registry. *Am Heart J* 2014;167:384-392.
  106. Michael TT, Karpaliotis D, Brilakis ES, Abdullah SM, Kirkland BL, Mishoe KL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Impact of prior coronary artery bypass graft surgery on chronic total occlusion revascularisation: insights from a multicentre US registry. *Heart*. 2013;99(20):1515-1518.
  107. Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB, Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. *Lancet*. 2013 Aug 30. doi:pii: S0140-6736(13)61782-1.
  108. Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, Kang HJ, Koo BK, Oh BH, Park YB, Kandzari DE, Cohen DJ, Hwang SS, Kim HS. Biodegradable-polymer drug-eluting stents versus bare metal stents versus durable-polymer drug-eluting stents. A systematic review and Bayesian approach network meta-analysis. *Eur HeartJ* 2014; doi:10.1093/eurheartj/eh570.
  109. Howard JP, Cole GD, Sievert H, Bhatt D, Papademetriou V, Kandzari DE, Davies JE. Unintentional overestimation of an expected antihypertensive effect in drug and device trials: mechanisms and solutions. *Int J Cardiol* 2014;172:29-35.
  110. Michael TT, Karpaliotis D, Brilakis ES, Alomar M, Abdullah SM, Kirkland BL, Mishoe KL, Lembo N, Kalynych A, Carlson H, Banerjee S, Luna M, Lombardi W, Kandzari DE. Temporal trends of fluoroscopy time and contrast utilization in coronary chronic total occlusion revascularization: Insights from a multicenter United States registry. *Catheter Cardiovasc Interv* 2014;doi: 10.1002/ccd.25359.
  111. Michael TT, Karpaliotis D, Brilakis ES, Fuh E, Patel VG, Mogabgab O, Alomar M, Kirkland BL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi W, Kandzari DE. Procedural outcomes of revascularization of chronic total occlusion of native coronary arteries (from a multicenter United States registry). *Am J Cardiol* 2013;112:488-492.
  112. Michael TT, Karpaliotis D, Brilakis ES, Abdullah SA, Kirkland BL, Mishoe KL, Lembo N, Kalynych A, Carlson H, Banerjee S, Lombardi WL,

- Kandzari DE. Impact of Prior Coronary Artery Bypass Graft Surgery on Chronic Total Occlusion Revascularization: Insights from a Multicenter US Registry. *Heart* 2013;99:1515-1518.
113. Navarese EP, Kowalewski M, Cortese B, Kandzari D, Dias S, Wojakowski W, Buffon A, Lansky A, Angelini P, Torguson R, Kubica J, Kelm M, Jan de Boer M, Waksman R, Suryapranata H. Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. *Atherosclerosis* 2014;233:224-231.
  114. Gao Z, Xu B, Yang Y, Kandzari DE, Sun Y, Qiao S, Wu Y, Yan H, Yuan J, Chen J, Shao Y, Gao R. Transradial versus transfemoral method of two-stent implantation for true bifurcation lesions: comparison of immediate and long-term outcomes. *J Interv Cardiol* 2014;9999:1-9.
  115. Christopoulos G, Karpaliotis D, Alaswad K, Lombardi W, Grantham A, Rangan BV, Kotsia AP, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Garcia S, Banerjee S, Thompson CA, Brilakis ES. The efficacy of "hybrid" percutaneous coronary intervention in chronic total occlusions caused by in-stent restenosis: Insights from a US multicenter registry. *Catheter Cardiovasc Interv.* 2014 doi: 10.1002/ccd.25465.
  116. Christopoulos G, Karpaliotis D, Alaswad K, Lombardi W, Grantham A, Rangan BV, Kotsia AP, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Garcia S, Banerjee S, Thompson CA, Brilakis ES. Application of the "hybrid Approach" to chronic total occlusions in patients with prior coronary artery bypass surgery (from a contemporary multicenter US registry. *Am J Cardiol* 2014;113:1990-1994.
  117. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negotia M, Cohen SA, Oparil S, Rocha-Singh K, Townsend RR, Bakris GL for the SYMPPLICITY HTN-3 Investigators. A randomized, controlled trial of renal denervation for resistant hypertension. *N Engl J Med* 2014; 10.1056/NEJMoa1402670
  118. Pancholy SB, ShanthavG, Patel TM, Sobotka PA, Kandzari DE. Meta-analysis of the effect of renal denervation on blood pressure and pulse pressure in patients with resistant systemic hypertension. *Am J Cardiol* 2014;114:856-861.
  119. Bakris GL, Townsend RR, Liu M, Cohen SA, D'Agostino R, Flack JM, Kandzari DE, Katzen BT, Leon MB, Mauri L, Negoita M, O'Neill WW, Oparil S, Rocha-Singh K, Bhatt DL; SYMPPLICITY HTN-3 Investigators. Impact of renal denervation on 24-hour ambulatory blood pressure: results from SYMPPLICITY HTN-3. *J Am Coll Cardiol* 2014 doi: 10.1016/j.jacc.2014.05.012



120. Galassi A, Grantham A, Kandzari D, Lombardi W, Moussa I, Thompson C, Werner G, Chambers C, Brilakis E. Percutaneous treatment of coronary chronic total occlusions part 1: rationale and outcomes. *Interventional Cardiology Review* 2014;9(3):201-208.
121. Christopoulos G, Menon RV, Karmaliotis D, Alaswad K, Lombardi W, Grantham A, Patel VG, Rangan BV, Kotsia AP, Lembo N, Kandzari D, Carlson H, Garcia S, Banerjee S, Thompson CA, Brilakis ES. The efficacy and safety of the "hybrid" approach to coronary chronic total occlusions: insights from a contemporary multicenter US registry and comparison with prior studies. *J Invasive Cardiol.* 2014;26:427-432.
122. Galassi A, Grantham A, Kandzari D, Lombardi W, Moussa I, Thompson C, Werner G, Chambers C, Brilakis E. Percutaneous treatment of coronary chronic total occlusions part 2: technical approach. *Interventional Cardiology Review* 2014;9(3):208-213.
123. Foran JP, Jain AK, Casserly I, Kandzari DE, Rocha-Singh KJ, Witkowski A, Katzen BT, Deaton D, Balmforth P, Sobotka PA. The ROX Coupler: creation of a fixed Ilio-femoral arteriovenous anastomosis for the treatment of systemic arterial hypertension, exploiting the physical properties of the arterial vasculature. *Cathet Cardiovasc Intervent* 2015;85:880-886.
124. Carlino M, Magri CM, Uretsky BF, Brilakis ES, Walsh S, Spratt JC, Hanratty C, Grantham JA, Rinfret S, Thompson CA, Lombardi WL, Galassi AR, Sianos G, Latib A, Garbo R, Karmaliotis D, Kandzari DE, Colombo A. Treatment of the chronic total occlusion: a call for action to the interventional community. *Cathet Cardiovasc Intervent* 2015;85:771-778.
125. Kereiakes DJ, Yeh RW, Massaro JM, Driscoll-Shempp P, Cutlip DE, Normand SLT, Steg PG, Gershlick AH, Darius H, Meredith IT, Ormiston J, Tanguay JF, Windecker S, Garratt KN, Kandzari DE, Lee DP, Simon DI, Iancu AC, Trebacz J, Mauri L, on behalf of the Dual Antiplatelet Therapy (DAPT) Study Investigators. Drug-eluting versus bare metal stents in patients receiving dual antiplatelet therapy. *JAMA* 2015;313:1113-1121.
126. Mauri L, Kereiakes DJ, Yeh RW, Driscoll-Shempp P, Cutlip DE, Steg PG, Normand SLT, Braunwald E, Wiviott SD, Cohen DJ, Holmes DR, Krucoff MW, Hermiller J, Dauerman H, Simon DI, Kandzari DE, Garratt KN, Lee DP, Pow TK, Ver Lee P, Rinaldi MJ, Massaro JM, on behalf of the Dual Antiplatelet Therapy (DAPT) Study Investigators. Dual antiplatelet therapy beyond one year after drug-eluting coronary stent procedures. *N Engl J Med* 2014
127. Navarese EP, Shulze V, Kowalewski M, Andreotti A, Kołodziejczak M, Kandzari DE, Rassaf T, Bartosz Gorny G, Brockmeyer M, Meyer C, Berti S, Kubica J, Kelm M, Valgimigli M. Comprehensive meta-analysis of safety and

- efficacy of bivalirudin vs heparin with or without GPIIb/IIIa inhibitor in patients with acute coronary syndrome. *JACC Cardiovasc Interv.* 2015 Jan;8(1 Pt B):201-13. doi: 10.1016/j.jcin.2014.10.003. Epub 2014 Nov 1
128. Kandzari DE, Bhatt DL, Brar S, Devireddy CM, Esler M, Fahy M, Flack JM, Katzen BT, Lea J, Lee DP, Leon MB, Ma A, Massaro J, Mauri L, Oparil S, O'Neill WW, Patel MR, Rocha-Singh K, Sobotka PA, Svetkey L, Townsend RR, Bakris GL. Predictors of blood pressure response in the SYMPPLICITY HTN-3 trial. *Eur Heart J* 2014
  129. Kandzari DE, Kini AS, Karmapliotis D, Moses JW, Tummala PE, Grantham JA, Orr C, Lombardi W, Nicholson WJ, Lembo NJ, Popma JJ, Wang J, Larracas C, Rutledge DR. Safety and effectiveness of everolimus-eluting stents in chronic total coronary occlusion revascularization: results from the Evaluation of the XIENCE Coronary Stent, Performance, and Technique in Chronic Total Oclusions (EXPERT CTO) Multicenter Trial. *J Am Coll Cardiol Interv* 2015;doi:10.1016/j.jcin.2014.12.238
  130. Alaswad K, Menon RV, Christopoulos G, Lombardi WL, Karmapliotis D, Grantham JA, Marso SP, Wyman MR, Pokala NR, Patel SM, Kotsia AP, Rangan BV, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Garcia SA, Thompson CA, Banerjee S, Brilakis ES. Transradial Approach for Coronary Chronic Total Occlusion Interventions: Insights from a Contemporary Multicenter Registry. *Cathet Cardiovasc Intervent* 2015 DOI: 10.1002/ccd.25827.
  131. Christopoulos G, Karmapliotis D, Wyman MR, Alaswad K, McCabe J, Lombardi WL, Grantham JA, Marso SP, Kotsia AP, Rangan BV, Garcia SA, Lembo N, Kandzari D, Lee J, Kalynych A, Carlson H, Thompson CA, Banerjee S, Brilakis ES. Percutaneous Intervention of Circumflex Chronic Total Occlusions Is Associated With Worse Procedural Outcomes: Insights From a Multicentre US Registry. *Can J Cardiol.* 2014 Dec;30(12):1588-94. doi: 10.1016/j.cjca.2014.07.007.
  132. Navarese EP, Kowalewski M, Kandzari D, Lansky A, Górny B, Kołtowski L, Waksman R, Berti S, Musumeci G, Limbruno U, van der Schaaf RJ, Kelm M, Kubica J, Suryapranata H. First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. *Open Heart.* 2014 Aug 21;1(1):e000064. doi: 10.1136/openhrt-2014-000064.
  133. Navarese EP, Kołodziejczak M, Schulze V, Gurbel PA, Tantry U<sup>4</sup>, Lin Y, Maximilian Brockmeyer M, Kandzari DE, Kubica JM,<sup>6</sup> D'Agostino RB, Kubica J, Volpe M, Agewall S, Kereiakes DJ, Kelm M. Effects of PCSK9 antibodies in adults with hypercholesterolemia. A systematic review and meta-analysis. *Annals Int Med* 2015 doi:10.7326/M14-2957.

134. White WB, Galis ZS, Henegar J, Kandzari DE, Victor R, Sica D, Townsend RR, Turner JR, Virmani R, Mauri L. Renal denervation therapy for hypertension: pathways for moving development forward. *J Am Soc Hypertens*. 2015;9:341-350.
135. Weber MA, Kirtane A, Mauri L, Townsend RR, Kandzari DE, Leon MB. Renal denervation for the treatment of hypertension: making a new start, getting it right. *J Clin Hypertens* 2015 May 14. doi: 10.1111/jch.12590.
136. Weber MA, Kirtane A, Mauri L, Townsend RR, Kandzari DE, Leon MB. Renal denervation for the treatment of hypertension: making a new start, getting it right. *Catheter Cardiovasc Interv* 2015 June 11. doi: 10.1002/ccd.26028.
137. Giustino G, MD, Baber U, Stefanini GG, Stone GW, Aquino M, Sartori S, Leon, Windecker S, Serruys PW, Morice MC, Wijns W, Camenzind E, Weisz G, Steg PG, Smits PC, Kandzari DE, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia G, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Impact of Clinical Presentation (Stable Angina Pectoris Versus Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction versus ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention with Drug-Eluting Stents. *Am J Cardiol* 2015
138. Christopoulos G, Wyman RM, Alaswad K, Karmaliotis, Lombardi W, Grantham JA, Yeh RW, Jaffer FA, Cipher DJ, Rangan BV, Christakopoulos GE, Kypreos M, Lembo N, Kandzari D, Garcia S, Thompson CA, Banerjee S, Brilakis ES. Clinical utility of the Japan–Chronic Total Occlusion Score in coronary chronic total occlusion interventions: results from a multicenter registry. *Circ Cardiovasc Interv*. 2015;8:e002171. doi: 10.1161/CIRCINTERVENTIONS.114.002171.
139. Flack J, Bhatt D, Kandzari DE, Brown D, Brar S, Choi JW, D'Agostino R, East C, Katzen BT, Lee L, Leon MB, Mauri L, O'Neill WW, Oparil S, Rocha-Singh K, Townsend RR, Bakris G. An analysis of the blood pressure and safety outcomes to renal denervation in African Americans and non-African Americans in SYMPPLICITY HTN-3 trial. *J Am Soc Hypertension* 2015.
140. Mahfoud F, Tunev S, Ewen S, Cremers B, Ruwart J, Schulz-Jander D, Liu M, Linz D, Davies J, Kandzari DE, Whitbourn R, Böhm M, Melder RJ. Impact of lesion placement on efficacy and safety of catheter-based radiofrequency renal denervation: the IVY approach. *J Am Coll Cardiol* 2015.
141. Giustino G, Baber U, Salianski O, Sartori S, Stone G, Leon MB, Aquino M, Stefanini G, Steg PG, Windecker S, O'Donoghue M, Wijns W, Serruys P, Valgimigli M, Morice MC, Camenzind E, Weisz G, Smits P, Kandzari D, von

Birgelen C, Dangas G, Cha JY, Galatius S, Jeger R, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim HS, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of new-generation drug-eluting stents in women at high-risk for atherothrombosis: from the women in innovation and drug-eluting stents (WIN-DES) collaborative patient-level pooled analysis. *Circ Cardiovasc Intervent* 2015.

142.

(b) (4)

Kandzari D, (b) (4)

2015. *In Press*

#### Non-refereed Publications

1. Kandzari DE, Behar VS, Sketch MH, Kereiakes DJ, Shimshak T, Broderick T, Young J, Runyon JP, Safian RD, Kern M, Colombo A. Extensive thrombus prior to elective percutaneous coronary intervention. *J Invasive Cardiol* 2001;13:38-52.
2. Kandzari, DE, Sketch NH. Saphenous vein graft disease: a left main equivalent. *J Invas Cardiol* 2001;13:665-668.
3. Kandzari DE, O'Shea JC, Kay J, Donahue M, Rao S. Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001. *Am Heart J* 2002;143:217-228.
4. Kandzari DE, O'Shea JC, Kay J, Donahue M, Rao S. Highlights from the American Heart Association annual scientific sessions 2001: November 11 to 14, 2001. *MDconsult.com*. February 11, 2002.
5. Nguyen CM, Kandzari DE, Peter RH, Harrington RA, Sketch MH. The bent stent. *J Invasive Cardiol* 2002;14:54-56.
6. Nguyen CM, Liao L, Trichon B, Saint-Jacques H, Kandzari DE, Donahue M, Nguyen C, Kaul P. Highlights from the American College of Cardiology Annual Scientific Sessions 2002: March 17 to 20. *Am Heart J* 2002;144:549-560.
7. Serruys PW, Meier B, Kandzari DE. Clinical decision making: treatment of bifurcation disease. *J Invas Cardiol* 2003.

8. Kandzari DE, Muhlestein JB. Clinical decision making: catheter-induced spasm of the left main coronary artery due to anatomic “kinking” in its course (commentary). *J Invas Cardiol* 2005;17:194.

### Chapters in Books

1. Gips SJ, Kandzari DE, Goldschmidt-Clermont PJ. Growth factor receptors, phospholipases, phospholipid kinases and actin reorganization. *Sem Cell Bio* 1994;5:201-208.
2. Kandzari DE, Goldschmidt-Clermont PJ. Regulation of the actin cytoskeleton by inositol phospholipid pathways. *Subcell Biochem* 1996;26:97-114.
3. Kandzari DE, Harrington RA. The coagulation system. Acute myocardial infarction and other ischemic syndromes, 2<sup>nd</sup> ed. 2000.
4. Kandzari DE, Jollis JG. Quality of coronary disease report cards. *Acute Coronary Syndromes*, 2<sup>nd</sup> ed. 2001.
5. Kandzari DE, Califf RM. Glycoprotein IIb/IIIa inhibitors in cardiology: the future. In: *GP IIb/IIIa inhibitors in cardiology*, A.M. Lincoff, ed. Humana Press, Inc.: Totowa, NJ. 2003.
6. Stone G, Kandzari DE, Grimes C. Integrating Coronary Stents and Glycoprotein IIb/IIIa Inhibitors into a Mechanical Reperfusion Strategy: The CADILLAC and ADMIRAL Trials. In: *Management of Acute Myocardial Infarction*. JE Tchong, ed. 2003.
7. Kandzari DE, Harrington RA. The coagulation system. *Acute myocardial infarction and other ischemic syndromes*, 3<sup>rd</sup> ed. 2003.
8. (b) (4) Kandzari, DE, (b) (4)
9. Kandzari DE, (b) (4)
10. (b) (4) Kandzari DE, (b) (4)
11. (b) (4) Kandzari DE, (b) (4)

12. Duggirala HJ, Kandzari, DE, Gross TP. Cardiovascular devices: drug eluting stents. *Medical Device Epidemiology and Surveillance*. S. Lori Brown, ed. 2007.
13. Barker CM, Kandzari DE. Chronic Total Coronary Occlusions. D. Moliterno, ed. 2010.
14. Barsness GW, Kandzari DE. Elective intervention for stable angina or silent ischemia. *Textbook of Interventional Cardiology*. E. Topol, ed. 2011.
15. Kandzari DE. Foreword: Transradial Access: Techniques for Diagnostic Angiography and Percutaneous Intervention. H. Cohen, ed. 2013.
16. Kandzari DE. Treatment of chronic total coronary occlusions with drug-eluting stents: overview of angiographic and clinical outcomes. Waksman R, Saito S, eds. *Chronic Total Occlusions: A Guide to Recanalization*, Wiley-Blackwell, 2013.
17. Barsness GW, Kandzari DE. Elective intervention for stable angina or silent ischemia. *Textbook of Interventional Cardiology*. E. Topol, ed. 2014.
18. Kandzari DE. Chronic total occlusion revascularization. *Cardiovascular Intervention, A Companion to Braunwald's Heart Disease*. D. Bhatt, ed. 2014.
19. Kandzari DE, Yang YJ, Xu B, Gao RL. Transradial percutaneous revascularization for unprotected left main coronary artery disease: an evolution in evidence and technique. O. Bertrand, S.V. Rao, eds. 2015
20. Patel MR, Kandzari DE, Shah R, Harrington RA. Reading Clinical Trials. Fearon WF Yeung A Samady H, eds. *Interventional Cardiology*, McGraw Hill, 2015.

### **Published Scientific Reviews**

1. Kandzari DE, Tchong JT. Contrast nephropathy. Harrison's online textbook of medicine. harrisonsonline.com. August, 2000.
2. Kandzari, DE, editor. American College of Cardiology American Heart Association Guidelines for Percutaneous Coronary Intervention (Revision of the 1993 PTCA Guidelines) Pocket Guidelines. DCRI publications: 2001.
3. Goldschmidt-Clermont PJ, Kandzari DE, Khouri S, Ferrari M. Nanotechnology needs for cardiovascular sciences. *Biomedical Microdevices* 2001;3:83-88.

4. Kandzari DE, Califf RM. Target versus GUSTO IV: appropriate use of abciximab versus small molecule inhibitors for unstable angina and PCI. *Curr Opin Cardiol* 2002.
5. Goldschmidt-Clermont PJ, Kandzari DE, Sketch MH, Phillips HR. Inflammation, platelets, and GP IIb/IIIa inhibitors. *J Invas Cardiol* 2002;14 (Suppl):18-26E.
6. Kandzari DE, Mahaffey KW. Clinical experience with glycoprotein IIb/IIIa inhibitors in acute coronary syndromes. *J Intervent Cardiol* 2002;15:121-130.
7. Kandzari DE, Tcheng JE, Zidar JP. Coronary artery stents: evaluating new designs for contemporary percutaneous intervention. *Cathet Cardiovasc Intervent* 2002;56:562-576.
8. Kandzari DE, Zidar JP. Drug-eluting stents: new frontiers for contemporary percutaneous coronary intervention. *Harrison's online textbook of medicine*. harrisonsonline.com. November, 2002.
9. Mayes CE, Kandzari DE, Goldschmidt-Clermont PJ, Phillips HR. Complimentary use of glycoprotein IIb/IIIa inhibitors and drug-eluting stents in contemporary percutaneous coronary intervention. *J Invas Cardiol* 2002;14 (Suppl):36-46E.
10. Kandzari DE, Rebeiz AG, Wang A, Sketch MH, Jr. Contrast nephropathy: an evidence-based approach to prevention. *Am J Therapeutics* 2003;3:395-405.
11. Kandzari, DE. A rationale for chronic total coronary occlusion revascularization: an evidence-based review of clinical trials. *J Invas Cardiol* 2004;16 (Suppl):3-6.
12. Kandzari DE. Current concepts in the antithrombotic management of non-ST-elevation acute coronary syndromes. *Curr Cardiol Rep* 2004;6:279-286.
13. Kandzari DE. The challenges of chronic total coronary occlusions: an old problem in a new perspective. *J Intervent Cardiol* 2004;4:259-257.
14. Kandzari DE. Assessment of coronary stenosis severity and plaque characterization with multi-row detector CT angiography. *Consultations in Computed Tomography*, Vol. 108, August 2005.
15. Kandzari DE, Dery JP, Armstrong PW, Douglas DA, Zettler ME, Hidinger KG, Friesen AD, Harrington RA. MC-1 (pyridoxal-5'-phosphate): novel therapeutic applications to reduce ischemic injury. *Expert Opin Investig Drugs* 2005;14:1435-1442.
16. Singh KP, Patel MR, Zidar JP, Kandzari DE. Peripheral arterial disease: an overview of endovascular therapies and contemporary treatment strategies. *Rev Cardiovasc Med* 2006; 7:55-68.

17. Kandzari DE, Leon MB. Overview of pharmacology and clinical trials program with the zotarolimus-eluting Endeavor stent. *J Intervent Cardiol* 2006;19:405-413.
18. Tricoci PL, Newby LK, Kandzari DE, Harrington RA. Present and evolving role of eptifibatide in the treatment of acute coronary syndromes. *Expert Rev Cardiovasc Ther.* 2007 May;5(3):401-412.
19. Kandzari DE. Future perspectives on antithrombin and antiplatelet therapies: novel antiplatelet and antithrombin therapies. *Rev Cardiovasc Med.* 2006;7 Suppl 3:S43-52.
20. Kandzari DE. Evolving Antithrombotic Treatment Strategies for Acute ST-Elevation Myocardial Infarction. *Rev Cardiovasc Med.* 2006;7 Suppl 4:S29-37.
21. Kandzari DE. Anticoagulation in the cath lab: a contemporary approach. Introduction. *Rev Cardiovasc Med.* 2006;7 Suppl 3:S1-2.
22. Gershlick A, Kandzari DE, Leon MB, Wijnd W, Meredith IT, Fajadet J, Popma JJ, Fitzgerald PJ, Kuntz RE, for the ENDEAVOR Investigators. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. *Am J Cardiol* 2007;100:45M-55M.
23. Barker CS, Kandzari DE. Sirolimus-eluting Cypher stent: a standard of comparison. *Cardiac Interv Today*, September 2008;1-5.
24. Nayak K, White AA, Cavendish JJ, Barker CM, Kandzari DE. Anaphylactoid reactions to radiocontrast agents: prevention and treatment in the cardiac catheterization laboratory. *J Invas Cardiol* 2009;21:548-551.
25. Kandzari DE. Development and clinical performance of the zotarolimus-eluting Endeavor coronary stent. *Expert Rev Med Devices* 2010;7:449-459.
26. Gunda S, Kandzari DE, Kirtane AJ. The end of ENDEAVOR IV: the stent comparison trial's final follow-up. *Expert Rev Cardiovasc Ther.* 2013;11(8):941-943.

### **Editorials, Position, and Background Papers**

1. Kandzari, Goldschmidt-Clermont PJ. Statins and sudden cardiac death. *JAMA* 1999;281:415.



2. Kandzari DE, Tcheng JT, Harrington RA, Sketch MH. “Rescue” glycoprotein IIb/IIIa therapy: bailing out of an already sunken ship. *J Invas Cardiol* 2000.
3. Kandzari DE, Jollis JG. Cardiology, for what it’s worth. *Am Heart J* 2000;139:392-393.
4. Kandzari DE, Goldschmidt PJ. Platelet polymorphisms and ischemic heart disease: moving beyond traditional risk factors. *J Am Coll Cardiol* 2001;38:1028-1032.
5. Kandzari DE, Goldschmidt PJ. Making positive out of negative trials. *Am Heart J* 2002;143:950-951.
6. Rebeiz A, Kandzari DE, Wang A, Sketch MH. Contrast nephropathy—time for affirmative action. *J Invas Cardiol* 2003;15:23-25.
7. Kandzari DE, Mark DB. Intracoronary brachytherapy: time to sell short? *Circulation* 2003;106:646-648.
8. Kandzari DE, Tcheng JE. Double Negatives. *Am Heart J* 2003;145:9-11.
9. Kandzari DE. Carbon-coated stents. *Evidence based Cardiovasc Med* 2004;8:344-345.
10. Gurbel PA, Kandzari DE. Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. [www.tct.md.com](http://www.tct.md.com), August 21, 2006.
11. Kandzari DE. Drug-eluting stent thrombosis: it’s never too late. *Nat Med* 2006;3:638-639.
12. Gurbel PA, Kandzari DE. Stent thrombosis associated with first-generation drug-eluting stents: issues with antiplatelet therapy. *Neth Heart J* 2007;15(4):148-150.
13. Brown R, Teirstein PS, Kandzari DE. Quality of life with PCI versus medical therapy in stable coronary disease. *N Engl J Med* 2008;359:2291.
14. Price MJ, Kandzari DE, Teirstein PS. Change we can believe in: the hyper-evolution of percutaneous coronary intervention for unprotected left main disease with drug-eluting stents. *Circulation Intervent* 2008. *Circulation Intervent* 2008;1:164-166.
15. Kandzari, DE. Import and export of interventional technique: something to declare at the border. *J Am Coll Cardiol Interv* 2009;2:843-845.
16. Kandzari, DE. Biodegradable polymer and permanent polymer drug-eluting stents: at the crossroads of evidence and expectation. *Future Medicine* 2012.

17. Kandzari DE, Grantham JA, MD, Lombardi W, Thompson C. Not all subintimal chronic total occlusion revascularization is alike. *J Am Coll Cardiol*. 2013 Mar 28. doi:pii: S0735-1097(13)01238-2. 10.1016/j.jacc.2013.02.055.
18. Kandzari DE, King SB. A passive limitation to equal access in clinical trials: the Medicare review process. *J Am Coll Cardiol Interv* 2013;6:640-641.
19. Kandzari DE, Sobotka PA. Ready for a marathon, not a sprint: renal denervation therapy for treatment-resistant hypertension. *J Am Coll Cardiol* 2013; doi:10.1016/j.jacc.2013.07.047.
20. Kandzari DE. One size does not fit all. *J Am Coll Cardiol* 2015;65:816-819.

### **Professional Awards and Special Recognitions**

2015 Atlanta Magazine, *Atlanta's Top Doctors*

2015 Montague Boyd Excellence in Publishing Award

2014 Atlanta Magazine, *Atlanta's Top Doctors*

2013 Atlanta Magazine, *Atlanta's Top Doctors*

2012 U.S. News and World Report, Top 1% of Nation's Cardiologists

2013 Montague Boyd Excellence in Publishing Award

2012 Atlanta Magazine, *Atlanta's Top Doctors*

2011 Atlanta Magazine, *Atlanta's Top Doctors*

2007 Standard of Leadership Award, Johnson & Johnson

2003 TCT2003 Thomas J. Linnemeier Spirit of Interventional Cardiology Young Investigator Award

2002 Clinical Site Coordinators' Cardiology Research Award, Duke University

2001 Robert "Jess" H. Peter Award in Interventional Cardiology, Duke University

1999 Smith Kline Beecham Preceptorship Award in Cardiology

1995 E.E. Owen Award for Outstanding Clinical Achievement

1994 Duke University Medical Senior Scholarship Award

1993 Stanley J. Sarnoff Fellowship in Cardiovascular Science

1993 Alpha Omega Alpha Medical Honorary

1992 Joseph E. Markee Memorial Award in Anatomy

### **National Leadership Roles in Clinical Trials**

SHIELD II, Co-Principal Investigator

SPYRAL Program, Co-Principal Investigator

Biotronik Osiris Clinical Trial Program, Principal Investigator

BioNir DES Program, International Principal Investigator

SYMPPLICITY HTN 4, Co-Principal Investigator

SYMPPLICITY HTN 3, Steering Committee

Promus ELEMENT US Post Market Registry, Principal Investigator

EMERGE, Principal Investigator

EXPERT CTO, Principal Investigator

EXCEL, National Leader (PCI)

CYPRESS, Co-Principal Investigator

RES-ELUTION III, Co-Principal Investigator

SEASIDE, Co-Principal Investigator

ENDEAVOR IV, Co-Principal Investigator

ENDEAVOR III, Co-Principal Investigator

ACROSS-Cypher/ Total Occlusion Studies of Coronary Arteries 4, Principal Investigator

GRAVITAS, Chairman, Clinical Events Committee

Nesterone Randomized Trial, Data Safety Monitoring Committee

CROSS Trial, Principal Investigator

Sprinter Legend 1.25 Trial, Principal Investigator

ACROSS Registry, co-Principal Investigator

ANTI-INFLAM, Principal Investigator

Cardiac MRI and Chronic Total Occlusion Study, Principal Investigator

CINEMA, Principal Investigator

COMBAT, co-Principal Investigator

LOWTEMP, co-Principal Investigator

MEND-1, co-Principal Investigator

EVENT Drug Eluting Stent Registry, Steering Committee Member

MEND-CABG, Co- Principal Investigator

### **National Program Committees/ Professional Society Leadership**

ACC2006 Vascular Planning Committee, Co-chairperson

SCAI 2006 Annual Program Co-chairperson

2006 Emerging Techniques in Cardiovascular Imaging: Comparing the Old to the New:

2006 A Cardiologist's Guide to MRI, CTA, and Echo, Course Co-director

TCT2005, TCT2006 Organizational and Planning Committee  
 2008 Asian Interventional Cardiovascular Therapeutics, International Advisory Board  
 2008 Sarnoff Cardiovascular Endowment, Board of Directors  
 2008 19<sup>th</sup> Annual Scripps Clinic Coronary Interventions, Course Co-Director  
 2009 Chronic Total Occlusion Summit, Course Co-Director  
 2009 International Heart Forum, Transradial Intervention International Course, Course Co-Director  
 2009 20<sup>th</sup> Annual Scripps Clinic Coronary Interventions, Course Co-Director  
 2010 Chronic Total Occlusion Summit, Course Co-Director  
 2010 China Interventional Therapeutics, Scientific Committee Member  
 ACC2010/i2 Summit Program Committee  
 2010 21<sup>th</sup> Annual Scripps Clinic Coronary Interventions, Course Co-Director  
 2010 2<sup>nd</sup> Transradial Catheterization Therapeutics, China Heart Congress/International Heart Forum 2010, Co-Director  
 ACC2011/i2 Summit Program Committee  
 2011 Transcatheter Therapeutics Left Main Summit, Co-Director  
 2011 Society for Coronary Angiography and Interventions (SCAI) Annual Sessions, Program Committee  
 2011 Transcatheter Therapeutics (TCT), Scientific Program Organizational Committee  
 2011 22<sup>nd</sup> Annual Scripps Clinic Coronary Interventions, Course Co-Director  
 2011 International Technology Exchange, Sydney, Australia, Co-Director  
 2012 ACC i2 Summit Abstract Grading Committee, Co-Chair  
 2012 TCT Complex Coronary Interventions: Left Main and CTO Summit, Co-Director  
 2013 ACC TCT/i2 Summit Stable Angina Working Group, Chair  
 Circulatory Devices Panel Voting Member, Edwards Sapien Transcatheter Valve, Gaithersburg, MD, June 13, 2012  
 23<sup>rd</sup> Annual Scripps Clinic Coronary Interventions, Course Co-Director  
 Co-Director, 7<sup>th</sup> Annual Technology Exchange, Sydney, Australia, November 15-17, 2012  
 2013 SCAI CTO Regional Training Program, Co-Chair  
 2013 RADIAL International Academic Board  
 2013 Cardiovascular Revascularization Therapeutics (CRT2013) Program Committee  
 2013 Cardiology Napa Valley 2013, Co-Director  
 2013 SCAI 2013, Program Committee  
 2014 ACC I2 Summit, Co-Chair  
 Circulatory Devices Panel Voting Member, BLOCK HF Trial, Gaithersburg, MD, October 11, 2013  
 Circulatory Devices Panel Voting Member, WATCHMAN Trial, Gaithersburg, MD, December 8, 2013  
 Circulatory Devices Panel Voting Member, Extracorporeal Membrane Oxygenation, Gaithersburg, MD, June 2014  
 Circulatory Devices Panel Voting Member, WATCHMAN Trial, Gaithersburg, MD, October 7, 2014  
 2014 Chronic Total Occlusion and Left Main Summit, Co-Director  
 2015 American College of Cardiology I2 Summit, Chair  
 2015 Latin America Technology and Therapy Exchange Program, Co-Chair

2015 TCT 2015 Scientific Committee, member  
Circulatory Devices Panel Voting Member, Cangrelor, White Oak, MD, April 15, 2015  
2016 American College of Cardiology I2 Summit, Chair

### **Editorial/Reviewer Appointments and Responsibilities**

*Transradialworld.org*, Editorial Board  
*The Journal of Medicine*, Editorial Board  
*Progress in Cardiovascular Diseases*, Editorial Board  
*Global Atrial Fibrillation Stroke Prevention Steering Committee*, [www.theheart.org](http://www.theheart.org)  
*Antiplatelet Therapies Steering Committee*, [www.theheart.org](http://www.theheart.org)  
*American Heart Journal*, Guest Editor  
*American Heart Journal*, Editorial Board and Associate Editor (2005-2006)  
*Reviews in Cardiovascular Medicine*, Editorial Board  
*Future Cardiology*, Editorial Advisory Board  
*Journal of the American College of Cardiology*, Guest Editor  
*JACC Interventions*, Guest Editor  
*Clinical Research in Cardiology*, Editorial Board  
Reviewer: *American Heart Journal*, *American Journal of Cardiology*, *Circulation*,  
*Catheterization and Cardiovascular Interventions*, *Journal of the American College of Cardiology*, *JACC Interventions*, *Journal of the American Medical Association*,  
*Circulation Cardiovascular Interventions*, *Journal of Sexual Medicine*, *Lancet*

### **Past/Present Consultant/Advisory Appointments and Research/Grant Support**

Abbott Vascular, Consultant  
Alsios Corporation, Advisory board; research/grant support  
Bayer Healthcare, Global advisory board; research/grant support  
Boehringer Ingelheim, US advisory board  
Boston Scientific Corporation, Scientific advisory board; research/grant support  
Cordis Corporation, Consultant; research/grant support  
Edwards Lifesciences, Consultant  
Eli Lilly and Co., Advisory board; research/grant support  
Endomatrix, Inc., Scientific advisory board  
Foxhollow Technologies, Inc., Scientific advisory board; research/grant support  
Genentech, Advisory board  
General Electric Medical Systems, Medical advisory board; research/grant support  
Lumend, Inc. Redwood City, CA, Scientific advisory board  
Medicure, Inc.; Research/grant support  
Medtronic AVE, Inc., Scientific advisory board; research/grant support  
Millennium/Schering Plough Pharmaceuticals, Inc., Advisory board; research/grant support  
Novostent, Advisory board  
Micell Technologies, Consultant

## Organizations and Participation

Alpha Omega Alpha, member  
American College of Cardiology, Fellow  
American College of Physicians, Fellow  
American Heart Association, early career member  
Andreas Gruentzig Society, member  
Sarnoff Cardiovascular Endowment, Board of Directors member  
Society of Coronary Angiography and Interventions, Fellow  
Society of Coronary Angiography and Interventions, Development Committee Co-Chair

## Selected Invited Lectures/CME Events

1. Duke Cardiology Grand Rounds, May 2000. *Mechanical Circulatory Support*
2. Medicine Grand Rounds, Rex Hospital, Raleigh, NC, 2000. *Cardiovascular Disease in Women*
3. Duke Clinical Research Conference, October 2001. *Megatrial in Aspirin Dosing*
4. Duke Clinical Research Conference, October 2002. *Lowering Adverse Outcomes with Temperature Regulation (LOWTEMP)*
5. Transcatheter Therapeutics (TCT) 2002, Washington, DC, September 2002. *Chronic Total Occlusions in Peripheral Arterial Disease*
6. Transcatheter Therapeutics 2002, September 2002. *Therapeutic Hypothermia as Adjunctive Therapy in Primary PCI*
7. Cardiovascular Associates 21<sup>st</sup> Annual Symposium on Cardiovascular Disease, Louisville KY, October 2002. *Contemporary Management of Acute Coronary Syndromes*
8. 13<sup>th</sup> Annual William Beaumont/Duke University Cardiovascular Conference, Beaver Creek, CO, Faculty, February, 2003. *Update on Chronic Total Occlusions*
9. Medicine Grand Rounds, Ochsner Institute, New Orleans, LA, May 2003. *Contemporary Management of Acute Myocardial Infarction*
10. Vascular Strategies Summit, Chicago, IL, May 2003. *Update in ST-Elevation Myocardial Infarction*
11. Duke Stent Symposium, Faculty, Pinehurst, NC, May 2003. *Novel Catheters for Percutaneous Coronary Intervention*
12. Paris Revascularization Course, Paris, France, May 2003. *Endovascular Cooling as Adjunctive Therapy in AMI*
13. ESPRIT investigator's close-out meeting, Miami, FL, May 2003. *Inflammation and ACS*
14. American College of Cardiology, Colorado Chapter, Denver, CO, July 2003. *Antithrombotic Therapies in ACS and Contemporary PCI*

15. Medtronic Scientific Advisory Board, Minneapolis, MN, June 2003. *Angiogenesis for Peripheral Arterial Disease*
16. TCT2003 Faculty, Plenary Session, Washington, DC, September 2003. *Unconquered Frontiers: Chronic Total Coronary Occlusions*
17. TCT2003 Faculty, Washington, DC, September 2003. *Plenary Session: New Solutions for Old Problems: Chronic Total Occlusions*
18. TCT2003 Faculty, Washington, DC, September 2003. *ACROSS: Approaches to Chronic Occlusions Registry*
19. Cardiology Grand Rounds, Allegheny General Hospital, Pittsburgh, PA, October 2003. *Antithrombotic Therapies in the Management of ACS and in Contemporary PCI*
20. North American CTO Club Meeting Faculty, Lenox Hill Hospital, New York, December 2003. *A Rationale for Chronic Total Occlusion Revascularization: An Evidence-based Review of Clinical Trials*
21. National Teleconference Series, January 2004. *New Considerations on the Treatment of Patients with NSTEMI ACS*
22. Duke Heart Center, Regional Symposium, January 2004. *Update in Peripheral Arterial Disease*
23. Vail Stent Symposium Faculty, Vail, CO, January 2004. *Evolving Beyond Platelet Inhibition: New Concepts for Antithrombotic Therapies in ACS and Contemporary PCI*
24. Vail Stent Symposium Faculty, Vail, CO, January 2004. *Novel Catheter-based Technologies in Percutaneous Coronary Revascularization*
25. 14<sup>th</sup> Annual William Beaumont/Duke University Cardiovascular Conference, Beaver Creek, CO, Faculty, February, 2004. *A Rationale for Chronic Total Occlusion Revascularization: An Evidence-based Review of Clinical Trials*
26. 14<sup>th</sup> Annual William Beaumont/Duke University Cardiovascular Conference, Beaver Creek, CO, Faculty, February, 2004. *Unstable Blood: Inflammation in Cardiovascular Disease*
27. Duke Clinical Research/ US FDA symposium on approval of new technologies in coronary revascularization, ACC Heart House, February 2004. *Participant*
28. Texas Heart Institute, Cardiology Grand Rounds, February 2004. *Evolving Beyond Platelet Inhibition: New Concepts for Antithrombotic Therapies in ACS and Contemporary PCI*
29. Interventions 2004 Faculty, Atlanta, GA, April 2004. *Update in Chronic Total Occlusion Revascularization: New Solutions for Old Problems*
30. 2004 American College of Cardiology Scientific Sessions, New Orleans, LA, 2004. *Complications in PCI: Chronic Total Occlusions*
31. 2004 European Society of Cardiology Scientific Sessions, Munich, Germany, August 2004. *ENDEAVOR 4: Randomized trial of the ABT-578 drug-eluting Endeavor stent with the TAXUS stent*
32. TCT2004 Faculty, Washington, DC, September 2004. *Plenary Session: A Rationale for Chronic Total Coronary Occlusion Revascularization: An Evidence-based Review of Clinical Trials and Technology*

33. New Cardiovascular Horizons, New Orleans, LA, October 2004. *New Perspectives on Antithrombotic Therapy and Drug-Eluting Stents in Contemporary Percutaneous Coronary Intervention*
34. Cardiology Grand Rounds, Rush University, Chicago, IL, November, 2004. *An Evolution of Antithrombotic Therapies in ACS and Contemporary PCI*
35. International Symposium of Cardiology: Procordis 40<sup>th</sup> Anniversary, Niteroi Hospital, Niteroi, Brasil, December 3, 2004. *Unstable Blood: Inflammation, Vulnerable Plaque, and Cardiovascular Disease. Identification, Implications, and Treatment of Unstable Coronary Lesions.*
36. International Symposium of Cardiology: Procordis 40<sup>th</sup> Anniversary, Niteroi Hospital, Niteroi, Brasil, December 4, 2004. *Unconquered Frontiers in Contemporary PCI: An Evidence-based Rationale for PCI in a DES Era.*
37. International Symposium of Cardiology: Procordis 40<sup>th</sup> Anniversary, Niteroi Hospital, Niteroi, Brasil, December 4, 2004. *Diagnostic and Therapeutic Potential of Stem Cells in Cardiovascular Disease: Steps Closer to Finding the Fountain of Youth*
38. 18<sup>th</sup> Annual Meeting of the Japanese Coronary Association, December 10, 2004, Kumamoto, Japan. *Evolving Understanding of Antithrombotic Therapies in Non-ST Elevation Acute Coronary Syndromes and Percutaneous Coronary Intervention.*
39. 18<sup>th</sup> Annual Meeting of the Japanese Coronary Association, December 10, 2004, Kumamoto, Japan. *Unconquered Frontiers—The Challenge of Complex Coronary Intervention.*
40. Whistler Course, January 29, 2005, Whistler, Canada. *An Evidence-based Rationale for CTO Revascularization.*
41. Cardiology Grand Rounds, February 2, 2005, Shands Hospital, Jacksonville, FL. *Complex Lesion Treatment with DES in Contemporary PCI.*
42. Chronic Total Occlusion Summit, Cardiovascular Research Foundation, February 4, 2005, New York, New York. *An Evidence-based Rationale for CTO Revascularization: Review of Evidence and Appraisal of New Technologies.*
43. Chronic Total Occlusions, Meet the Experts, March 7, 2005, Orlando, FL. American College of Cardiology 2005 Scientific Sessions.
44. ENDEAVOR Clinical Trials Program, March 5, 2005, Orlando Florida, Cardiovascular Research Foundation Drug Eluting Stent Revolution IV: A Critical Appraisal.
45. San Antonio Cardiovascular Society, April 21, 2005. *An Evidence-based Rationale for CTO Revascularization: Review of Evidence and Appraisal of New Technologies.*
46. 9<sup>th</sup> Annual Duke Spring Cardiovascular Symposium, April 23, 2005, Pinehurst, NC. *Multi-row detector CT Angiography: New Perspectives on Noninvasive Coronary and Vascular Imaging.*
47. 14<sup>th</sup> Annual Scientific Sessions, Brazilian Society of Cardiology, April 27, 2005, Rio de Janeiro, Brasil. *The Vulnerable Atherosclerotic Plaque: Definition, Identification and Implications of Unstable Coronary Atherosclerotic Lesions.*



48. American College of Cardiology CT Coronary Angiography Review Course, April 30, 2005, Milwaukee, WI. *Indications, Guidelines and Appropriateness Criteria for CTA – Where We Are and Where We Need To Go*
49. Providence Heart and Vascular Institute Research Symposium, May 9, 2005, Portland, Oregon. *New Insights in Pharmacotherapy for the Interventional Cardiologist.*
50. Abbott Vascular Webcast, The Challenges of Chronic Total Occlusions: Overview of Rationale, Technique and Technology (CME event), June 1, 2005. *Novel Techniques and Technologies for CTO Revascularization.*
51. Intervention2005, Las Vegas, NV, June 3, 2005. *Treatment Strategies for Non-ST-Elevation Acute Coronary Syndromes.*
52. 14<sup>th</sup> Interventional Cardiology Symposium, Montreal Heart Institute, June 16-17, 2005, Montreal, Canada. *Chronic Total Occlusion Revascularization: New Perspectives on an Old Problem.*
53. Hong Kong Sanatorium and Hospital Annual Scientific Meeting, June 27, 2005, Hong Kong. *Endeavor Clinical Trials Program and Endeavor II Trial Results.*
54. MedReviews in Cardiovascular Medicine, July 15, 2005 (Co-chairperson). *Novel Antiplatelet and Antithrombin Therapies.*
55. Summer in Seattle SIS 2005 Interventional Program, July 20, 2005, Seattle, WA. *Update on Rationale and Technologies for CTO Revascularization.*
56. Malaysian Cardiovascular Interventional Symposium 2005, July 27-30, 2005, Kuala Lumpur, Malaysia. *Bare Metal Stents versus Drug-eluting Stents: Their Role in PCI Today.*
57. New Cardiovascular Horizons Meeting, October 26, 2005, Miami, FL. *Atherosclerosis, Plaque Biology and Genomics: Potential for Disease Management and Diagnosis Through Gene Expression Profiling.*
58. 1<sup>st</sup> Annual Scientific Meeting of the Coronary Interventional Club of Thailand, November 25, 2005, Bangkok, Thailand. *Clinical Relevance and Rationale for CTO Revascularization.*
59. 1<sup>st</sup> Annual Scientific Meeting of the Coronary Interventional Club of Thailand, November 25, 2005, Bangkok, Thailand. *Evidence-based Perspectives on Drug-Eluting Stents.*
60. 2<sup>nd</sup> International Cardiovascular Symposium, December 2, 2005, Niteroi, Brazil. *Clinical Approach to the Identification and Treatment of Renal Artery Stenosis.*
61. Columbia University Medical Center, Cardiac Catheterization Laboratory Grand Rounds, December 6, 2005, New York, New York. *Noninvasive Imaging for Interventionalists: Role of Noninvasive Imaging for Clinical Decision- Making in the Catheterization Laboratory.*
62. STRIVE Program: Strategies and Therapies for Reducing Ischemic and Vascular Events, December 15, 2005, Boston, MA. *Frequency and Implications of Stent Thrombosis Following DES Use in Contemporary Clinical Practice: Overview of the Incidence, Predictors and Implications of Drug-Eluting Stent Thrombosis.*
63. PCI Summit 2006, January 11, 2006, Park City, Utah. *Latest Advances in Atherectomy and Debulking Techniques.*
64. PCI Summit 2006, January 14, 2006, Park City, Utah. *Role of Noninvasive Imaging with CT Angiography for Cath Lab Decision Making.*

65. PCI Summit 2006, January 14, 2006, Park City, Utah. *The Paclitaxel -Eluting Stent: From Taxus to Liberte and into the Future: The Boston Scientific DES Program.*
66. 15<sup>th</sup> Annual Whistler Interventional Cardiology Meeting, January 24, 2006, Whistler, BC, Canada. *An Evidence-based Rationale for Successful CTO Revascularization.*
67. American Society of Echocardiography, February 2, 2006, Marco Island, Florida. *ABC's of Coronary CTA: Getting Started with Coronary CT Angiography.*
68. American Society of Echocardiography, February 3, 2006, Marco Island, Florida. *Noninvasive Imaging for Peripheral Arterial Disease: Perspectives on CT and MR for Assessment of Atherosclerotic Peripheral Arterial Disease.*
69. 15<sup>th</sup> Annual Cardiovascular Conference at Beaver Creek, February 15, 2006, Avon, Colorado. *Myocardial Perfusion in Acute MI.*
70. Morgan Stanley 9<sup>th</sup> Annual Interventional Cardiology Conference, February 22, 2006, New York, NY. *State of the Art for Coronary Stents: Balancing Safety and Efficacy.*
71. 3<sup>rd</sup> International Chronic Total Occlusion Summit, February 23, 2006, New York, NY. *The Latest Evidence Based Medicine in CTO Therapy: Emphasis on Drug-Eluting Stents.*
72. Singapore Live 2006, February 28, 2006, Singapore. *Late Loss and its Relationship to events after DES Stenting.*
73. Singapore Live 2006, February 28, 2006, Singapore. *US Techniques/Approaches to CTO.*
74. ACC 2006, March 11, 2006, Atlanta Georgia. *Enter the Drug-Eluting Stent Revolution V: A Critical Appraisal of DES, Safety, and Efficacy.*
75. ACC 2006, March 13, 2006, Atlanta Georgia. *Endeavor Trials - Drug-Eluting Stents: Results from Clinical Trials.*
76. ACC 2006, March 14, 2006, Atlanta, Georgia. *ACCEL Interview – ENDEAVOR Trials.*
77. ACC 2006, March 14, 2006, Atlanta, Georgia. *Chronic Total Occlusions: Percutaneous Coronary Intervention.*
78. Med Reviews CME Event, March 18, 2006, New York, NY. *Anticoagulation in the Cath Lab: A Contemporary Approach. New Developments in Antiplatelet and Anticoagulant Therapy.*
79. Atlanta Cardiology Catheterization Lab Approaches for Success VII, March 22, 2006, Atlanta, GA. *Chronic Total Occlusions: Other Complex / Challenging Cases.*
80. 12<sup>th</sup> Annual Interventional Cardiology Fellows Course, March 29, 2006, San Jose, CA. *CTO Angioplasty I: Pathology, Rationale and Predictors of Success.*
81. Angioplasty Summit 2006 TCT Asia Pacific, April 26, 2006, Seoul, Korea. *Drug Eluting Stent Summit I. Overview of Endeavor Clinical Trials Program.*
82. Angioplasty Summit 2006 TCT Asia Pacific, April 26, 2006, Seoul, Korea. *Drug Eluting Stent Thrombosis: Balancing Efficacy with Safety.*
83. Angioplasty Summit 2006 TCT Asia Pacific, April 27, 2006, Seoul Korea. *Chronic Total Occlusions: Evidence Based Rationale for Recanalization and DES.*

84. SCAI 29<sup>th</sup> Annual Scientific Sessions, May 10, 2006, Chicago, IL. *Drug Eluting Stents: Complex Lesions, The Latest Data.*
85. SCAI 29<sup>th</sup> Annual Scientific Sessions, May 12, 2006, Chicago, IL. *Chronic Total Occlusions: Why Open CTO's; Whom Do We Treat?*
86. Euro PCR 2006, May 18, 2006, Paris, France. *Chronic Total Occlusions: Advanced Strategies 2006 from Japan.*
87. 8<sup>th</sup> Annual International Symposium on MDCT, June 17, 2006, San Francisco, CA. *Evidence- Based Rationale for Coronary CT Angiography.*
88. 8<sup>th</sup> Annual International Symposium on MDCT, June 17, 2006, San Francisco, CA. *Non Invasive Imaging with CT Angiography for Interventional Cardiology Applications.*
89. 15<sup>th</sup> Annual Japanese Society of Interventional Cardiology, June 23, 2006, Fukuoka, Japan. *Stent Migration or Fracture? Clinical Implications of Stent Fracture Following Total Occlusion revascularization.*
90. 3<sup>rd</sup> Malaysian Cardiovascular Interventional Symposium with Live Transmission, July 12, 2006, Kuala Lumpur, Malaysia. *Stent Malapposition: Is it Clinically Relevant?*
91. 3<sup>rd</sup> Malaysian Cardiovascular Interventional Symposium with Live Transmission, July 13, 2006, Kuala Lumpur, Malaysia. *ENDEAVOR Trials/ Registry.*
92. 3<sup>rd</sup> Malaysian Cardiovascular Interventional Symposium with Live Transmission, July 14, 2006, Kuala Lumpur, Malaysia. *CTO: The Last Frontier?*
93. Summer in Seattle SIS 2006, July 21, 2006, Bellevue, Washington. *CTO Traditional and Novel Approaches.*
94. Summer in Seattle SIS 2006, July 22, 2006, Bellevue, Washington. *Chronic Total Occlusions: Techniques and Approaches.*
95. PCI Summit Meeting, January 2007, Salt lake City, Utah. *Contemporary PCI with the Cypher Stent: Standard of Compare and Standard of Comparison.*
96. British Cardiac Interventional Society Meeting, January 2007, London, England. *Contemporary PCI with the Cypher Stent: Standard of Compare and Standard of Comparison.*
97. Catheter Revascularization Therapies Conference, FDA Town Hall Meeting, February 2007, Washington, DC. *Cordis Corporation Perspective on FDA Guidance for Drug-Eluting Stents.*
98. American College of Cardiology Scientific Sessions, March 2007, New Orleans, LA. *Debate: Endovascular Therapy is Treatment of Choice for Treatment of Intermittent Claudication.*
99. Angioplasty Summit Cardiovascular Conference, April 2007, Seoul, Korea. *Clinical Considerations for Patient Selection in CTO Revascularization.*
100. Stanford Center for Cardiovascular Technology Symposium, May 30, 2007, Palo Alto, CA. *Future Technologies from the Cordis Corporation.*
101. Japanese Society of Interventional Cardiology, June 2007, Fukuoka, Japan. *Understanding and Applying the Evidence from Randomized Clinical Trials, Registries and Meta-analyses: Is There a Common Theme?*
102. Malaysia Live Cardiovascular Conference, July 2007, Kuala Lumpur, Malaysia. *Clinical Considerations for Patient Selection in CTO Revascularization.*

103. Malaysia Live Cardiovascular Conference, July 2007, Kuala Lumpur, Malaysia. *Exploring New Frontiers in PCI: CTO Revascularization in 2007.*
104. Malaysia Live Cardiovascular Conference, July 2007, Kuala Lumpur, Malaysia. *Noninvasive Imaging for Interventional Cardiologists: Perspectives on Non-invasive Coronary and Peripheral Arterial Imaging for Cath Lab Decision Making.*
105. TOPIC Meeting, July 21, 2007, Tokyo, Japan. *Drug-Eluting Stent Landscape and the Cordis Clinical Trials Program.*
106. Transcatheter Therapeutics 2007, October 2007, Washington, D.C. *Approaches to Chronic Occlusions with Sirolimus Stents: the ACROSS-Cypher/Total Occlusion Study of Coronary Arteries-4 Trial.*
107. Great Wall Cardiovascular Society, October 2007, Beijing, China. *Antiplatelet Therapy and Drug-Eluting Safety: Risks and Benefits of Antiplatelet Therapy in an Era of Drug-Eluting Stents.*
108. Great Wall Cardiovascular Society, October 2007, Beijing, China. *Late Drug-Eluting Stent Thrombosis: Incidence, Predictors and Clinical Implications of Stent Thrombosis.*
109. Medicine Grand Rounds, Loyola University, October 2007, Chicago, IL. *Drug-Eluting Coronary Stent Safety in 2007: Overview of the Incidence, Predictors and Clinical Implications of Drug-Eluting Stent-related Adverse Events.*
110. Cardiology Grand Rounds, Scripps Green Hospital, October 2007, La Jolla, CA. *Predicting Late Drug-Eluting Coronary Stent Thrombosis.*
111. Australia-New Zealand Cardiovascular Society Conference (ANZET), November 2007, Christ Church, NZ. *Overview of Cordis Clinical Trials Program.*
112. 3<sup>rd</sup> Annual Coronary Interventional Society of Thailand Cardiovascular Conference, November 2007, Bangkok, Thailand. *Drug-Eluting Coronary Stent Safety and Efficacy in 'Real World' Practice.*
113. 3<sup>rd</sup> Annual Coronary Interventional Society of Thailand Cardiovascular Conference, November 2007, Bangkok, Thailand. *Endovascular Treatment for Peripheral Arterial Chronic Total Occlusions: Clinical Outcomes, Challenges and Potential for Disease Management.*
114. 16<sup>th</sup> Annual Beaver Creek Cardiovascular Conference, February 2007, Beaver Creek, CO. *PCI in Perspective: Do Clinical Trials Influence Clinical Decision Making in Percutaneous Coronary Intervention?*
115. 3-C Conference on Advances in Cardiovascular Medicine, January 2008, Ahmedabad, India. *Drug Eluting Stents are the Treatment of Choice in Eligible Patients with Coronary Disease: The Evolving Efficacy and Safety of Drug-Eluting Stents.*
116. 3-C Conference on Advances in Cardiovascular Medicine, January 2008, Ahmedabad, India. *Perioperative Management of Patients with Coronary Stents. Overview of Preoperative Assessment and Perioperative Management of Stent Patients Undergoing Non-cardiac Surgery.*
117. 3-C Conference on Advances in Cardiovascular Medicine, January 2008, Ahmedabad, India. *Perioperative Management of Patients with Coronary Stents.*

- Overview of Preoperative Assessment and Perioperative Management of Stent Patients Undergoing Non-cardiac Surgery.*
118. SingLive 2008, March 2008, Singapore. *Evidence-based Overview of Drug Eluting Stent Use in Chronic Total Occlusions: Results from the ACROSS/TOSCA-4 Trial.*
  119. SingLive 2008, March 2008, Singapore. *Clinical Considerations for Patient Selection in Chronic Total Occlusion Revascularization: Whom to Treat, Who Derives Benefit and What Can We Achieve?*
  120. SingLive 2008, March 2008, Singapore. *Drug Eluting Stent Outcomes in Real World Practice: Spectrum of Efficacy and Safety Among Differing Drug Eluting Stents.*
  121. SingLive 2008, March 2008, Singapore. *Drug Eluting Stent Outcomes in Real World Practice: Spectrum of Efficacy and Safety Among Differing Drug Eluting Stents.*
  122. Alliance of Cardiovascular Professionals 2008 Leadership Conference, March 27, 2008, Chicago, IL. *New Developments and Future Technologies in Cardiovascular Disease.*
  123. American College of Cardiovascular Administrators 19<sup>th</sup> Annual Leadership Conference, March 27, 2008, Chicago, IL. *Interventional Cardiology in Perspective: An Interplay of Clinical Trials, Public Opinion and Physician Perceptions.*
  124. 13<sup>th</sup> Angioplasty Summit- TCT Asia Pacific 2008, April 23, 2008, Seoul, Korea. *Comparative Trials of DES Safety and Efficacy Role of DES in Chronic Total Occlusions: Results of The ACROSS Trial Evaluating SES in Chronic Total Occlusions.*
  125. 13<sup>th</sup> Angioplasty Summit- TCT Asia Pacific 2008, April 24, 2008, Seoul, Korea. *Safety of Drug Eluting Stents in Diabetes.*
  126. Brazilian Society of Interventional Cardiology 2008, June 17, 2008, Recife, Brazil. *Current Perspectives on DES in Contemporary PCI: A Standard of Comparison, A Standard of Care.*
  127. 2008 Malaysian Live Cardiovascular Conference, July 9, 2008, Kuala Lumpur, Malaysia. *Diabetes in PCI: Therapeutic Challenge for a Global Epidemic.*
  128. 2008 Malaysian Live Cardiovascular Conference, July 9, 2008, Kuala Lumpur, Malaysia. *Diabetes in PCI: Therapeutic Challenge for a Global Epidemic. Endovascular Therapies for Lower Extremity Peripheral Arterial Disease: Clinical Outcomes, Challenges and Potential for Disease Management.*
  129. Cardiac and Peripheral Vascular CT 2008: What You Need to Know, September 4, 2008, Las Vegas, Nevada. *Who Should(n't) Have a Coronary CTA Exam?*
  130. Cardiac and Peripheral Vascular CT 2008: What You Need to Know, September 4, 2008, Las Vegas, Nevada. *Comparative Trials of Coronary CT Angiography and Cardiac Catheterization.*
  131. Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *Improvement in Left Ventricular Function After Successful CTO Recanalization: Frequency, Correlates and Clinical Implications.*

132. Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *New Bioabsorbable Polymer Drug Carrier Systems. The MICELL Rapid Absorption Polymer DES System: Design Concepts and Experimental Studies.*
133. Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *Plenary Lecture: Clinical Considerations for CTO Revascularization: Whom to Treat, Who Derives Benefit, and What Can We Achieve?*
134. Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *CTO Revascularization Revisited: Rationale, Patient Selection and Evolutionary Approach.*
135. Transcatheter Therapeutics 2008, October 2008, Washington, D.C. *The Great Debate. Adjunct Pharmacotherapy for Primary PCI: Heparin plus GP IIb/IIIa Inhibitors Must Still be Considered Standard of Care.*
136. American Heart Association Scientific Sessions, November 2008, New Orleans, LA. *Chronic Coronary Total Occlusions, State of the Art: Rationale for Chronic Total Occlusion Percutaneous Revascularization.*
137. Taiwan Transcatheter Therapeutics, January 2009, Taipei, Taiwan. *PCI in Perspective: Key Clinical Trials in Interventional Cardiology for 2009.*
138. Taiwan Transcatheter Therapeutics, January 2009, Taipei, Taiwan. *The Endeavor Resolute Clinical Trials Program.*
139. Taiwan Transcatheter Therapeutics, January 2009, Taipei, Taiwan. *Overview of the Long-Term Safety and Efficacy of the Endeavor Clinical Trial Program.*
140. Courage Quality of Life: How to Manage Patients with Unstable Angina. August 29, 2008, [www.theheart.org](http://www.theheart.org).
141. DES in Complex Patients: A Case-based Discussion. October 28, 2008, [www.theheart.org](http://www.theheart.org).
142. Drug-eluting Stents and Noncardiac Surgery. November 24, 2008, [www.theheart.org](http://www.theheart.org).
143. Why Warfarin Has Been the Mainstay of Anticoagulation and Antithrombin Therapy for Half a Century: Benefits and Limitations. November 28, 2008, [www.theheart.org](http://www.theheart.org).
144. Antiplatelet Options for ACS: the Changing Landscape. February 12, 2009, [www.theheart.org](http://www.theheart.org).
145. Emory Regional Cardiac Catheterization Conference, January 14, 2009, Atlanta, GA. *PCI in Perspective: Lessons Learned in Interventional Cardiology.*
146. Chronic Total Occlusion Summit, February 5, 2009, New York, NY and La Jolla, CA. *DES in CTO Revascularization: One Step Forward, Two Steps Back?*
147. Panvascular Summit, February 26, 2009, Park City, Utah. *Left Main Percutaneous Coronary Revascularization: Time for Changing the Standard of Care.*
148. CRT 2009, March 5, 2009, Washington, DC. *Impact of CTO Revascularization on Left Ventricular Function.*
149. CRT 2009, March 5, 2009, Washington, DC. *DES in Acute Myocardial Infarction: More Trials, But Still at Equipoise.*

150. CRT 2009, March 6, 2009, Washington, DC. *The Micell Rapid Absorption Polymer DES System.*
151. China Interventional Therapeutics, March 19, 2009, Beijing, China. *Key Clinical Trials in Interventional Cardiology for 2009.*
152. China Interventional Therapeutics, March 19, 2009, Beijing, China. *DES in Acute Myocardial Infarction: More Trials, But Still at Equipoise.*
153. China Interventional Therapeutics, March 19, 2009, Beijing, China. *Novel Endovascular Therapies for Lower Extremity Revascularization.*
154. American College of Cardiology Scientific Sessions, March 29, 2009, Orlando, FL. *The 'Optimal' Duration of Antiplatelet Therapy: Less is More, More or Less.*
155. American College of Cardiology Scientific Sessions, March 31, 2009, Orlando, FL. *Rationale for CTO Revascularization, ACC Fellows' Course.*
156. Assessing Long-term Risks and Benefits of Drug-eluting and Bare Metal Stents. March 29, 2009, [www.theheart.org](http://www.theheart.org).
157. What Happened at ACC 2009?: A Scripps Perspective. March 29, 2009, [www.theheart.org](http://www.theheart.org).
158. Cardiac Catheterization Access Sites: An International Perspective and Emphasis on Transradial Intervention. March 30, 2009, [www.theheart.org](http://www.theheart.org).
159. Fifth Annual Cardiology Symposium, Mother Frances Hospital, April 14, 2009, Tyler, TX. *Key Cardiovascular Clinical Trials for 2009.*
160. 14<sup>th</sup> Angioplasty Summit-TCT Asia Pacific 2009, April 22, 2009, Seoul, Korea. *Critical Review of Interventional Options for the SFA: Current Devices and Future Directions.*
161. 14<sup>th</sup> Angioplasty Summit-TCT Asia Pacific 2009, April 23, 2009, Seoul, Korea. *What is the Optimal Duration of Dual Antiplatelet Therapy Following DES Revascularization?*
162. 14<sup>th</sup> Angioplasty Summit-TCT Asia Pacific 2009, April 23, 2009, Seoul, Korea. *Outcomes of Zotarolimus Eluting Stents in Diabetes: Results from the Endeavor IV and E-Five Clinical Trials.*
163. 14<sup>th</sup> Angioplasty Summit-TCT Asia Pacific 2009, April 24, 2009, Seoul, Korea. *Rationale for Chronic Total Occlusion Revascularization.*
164. Innovations 2009, April 30, 2009, Washington, DC. *From Clinical Trials to Clinical Practice. When Should DES Be Used?*
165. SCAI 2009 Scientific Sessions, May 8, 2009, Las Vegas, NV. *Seeing is Believing: Use of Intravascular Ultrasound in Chronic Total Revascularization.*
166. SCAI 2009 Scientific Sessions, May 8, 2009, Las Vegas, NV. *Uncrossably Crossed Chronic Total Occlusions.*
167. Cardiology Grand Rounds, Sharp Memorial Hospital, May 22, 2009, San Diego, CA. *A Clinical Rationale for CTO Revascularization.*
168. Cardiology Grand Rounds, University of San Francisco, California, June 3, 2009, San Francisco, CA. *Unprotected Left Main Percutaneous Revascularization: Are We Ready to Change the Guidelines?*
169. Transradial Access for PCI. June 26, 2009, [www.theheart.org](http://www.theheart.org).
170. Hong Kong College of Cardiology, 17th Annual Scientific Congress, June 27, 2009, Hong Kong. *Drug-Eluting Stents in Acute Coronary Syndromes.*

171. Hong Kong College of Cardiology, 17th Annual Scientific Congress, June 27, 2009, Hong Kong. *New Drug-Eluting Stent Solutions for Complex Coronary Artery Disease.*
172. TOPIC 2009, July 16, 2009, Tokyo, Japan. *Left Main Percutaneous Revascularization: Influence of Stent Technique.*
173. TOPIC 2009, July 16, 2009, Tokyo, Japan. *SYNTAX in Clinical Practice: A Practical Approach to How the SYNTAX Trial Influences Clinical Decision Making.*
174. TOPIC 2009, July 16, 2009, Tokyo, Japan. *DAPT After DES Revascularization: Risk, Benefit and Still Much to Learn.*
175. Emerging Countries Interventional Symposium, August 13, 2009, Vienna, Austria. *Interventional Cardiology in Perspective: Past, Present and Future.*
176. PCI for Unprotected Left Main Disease: Are We There Yet? September 22, 2009, [www.theheart.org](http://www.theheart.org).
177. TCT 2009, September 21, 2009, San Francisco, CA. *The Resistant CTO: When a Lesion Won't Dilate.*
178. TCT 2009, September 21, 2009, San Francisco, CA. *Clinical Dilemmas for Multivessel Coronary Disease in 2009: Considerations for Revascularization Strategy, Relative Risk and Benefit*
179. 9<sup>th</sup> Annual Cardiovascular Symposium, October 9, 2009, Wailea, Maui. *PCI for Unprotected Left Main Disease: Are We Ready to Change Practice Guidelines?*
180. Cardiology Grand Rounds, Scripps Mercy Hospital, October 1, 2009, San Diego, CA. *TCT2009: Review of High Impact Clinical Trials.*
181. Cardiology Grand Rounds, Grossmont Hospital, October 21, 2009, San Diego, CA. *PCI in Perspective: Past, Present and Beyond. Lessons Learned in Interventional Cardiology and Future Directions.*
182. University of Texas-Southwestern 9<sup>th</sup> Annual Cardiovascular Symposium: Frontiers in Interventional Cardiology, October 26, Dallas, TX. *Clinical Considerations for Chronic Total Occlusion Revascularization. Whom to Treat, Who Derives Benefit, What Can We Achieve?*
183. 20<sup>th</sup> Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *Technical Considerations for Chronic Total Occlusion Revascularization: Advancement in Technique, Technology and Strategy.*
184. 20<sup>th</sup> Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *Impella 2.5 Hemodynamic Assist Technology: Overview of Technology and Device Performance.*
185. 20<sup>th</sup> Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *Key Clinical Trials for 2009: High Impact Trials that Influence Clinical Practice.*
186. 20<sup>th</sup> Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *Carotid Artery Stent Update 2009: Under Attack...and Fighting Back!*
187. 20<sup>th</sup> Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *SYNTAX in Clinical Practice: A Practical Approach to How the SYNTAX Trial Influences Clinical Decision Making.*



188. 20<sup>th</sup> Annual Scripps Interventions Course, October 28-30, 2009, San Diego. *FFR: Find and Fix it Right. Diagnostic and Therapeutic Utility of Hemodynamic Assessment.*
189. American Heart Association Scientific Sessions, November 14, 2009, Orlando, FL. *Evidence Basis for Percutaneous CTO Revascularization: Insight to Procedural and Clinical Outcomes from Contemporary Trials.*
190. American Heart Association Scientific Sessions and Fellows' Course, November 14, 2009, Orlando, FL. *Clinical Considerations for CTO Revascularization.*
191. International Technology Exchange, November 18, 2009, Sydney, Australia. *Considerations for Complex Coronary and Peripheral Revascularization.*
192. Scottsdale Interventional Forum, February 11, 2010, Scottsdale, AZ. *From Clinical Trials for Clinical Practice: Understanding Clinical Trials and Influence on Clinical Practice.*
193. Scottsdale Interventional Forum, February 11, 2010, Scottsdale, AZ. *Unprotected Left Main Disease: Moving Beyond a State of Clinical Equipoise.*
194. Scottsdale Interventional Forum, February 13, 2010, Scottsdale, AZ. *DES (R)evolution. 'Next Generation' DES: Evidence, Impact and Unmet Needs.*
195. *Optimizing Platelet Inhibition Through All Phases of Non-ST Segment Acute Coronary Syndromes (Simultaneous Webcast).* December 17, 2009, New York, New York.
196. 2010 Panvascular Summit, February 20, 2010, Salt Lake City, UT. *Who Should(n't) get a Coronary CT Angiogram? Diagnostic Challenges for a Revolutionary Technology.*
197. Grossmont Hospital Cardiology Grand Rounds, February 17, 2010. *Antiplatelet Therapy in Non-ST Segment Elevation Acute Coronary Syndromes.*
198. CRT2010, February 22, 2010, Washington, DC. *DAPT in Contemporary PCI. Risk, Benefit and Still Much to Learn.*
199. CRT2010, February 23, 2010, Washington, DC. *Endeavor DES Clinical Trials Program. From Clinical Trials to Clinical Practice: Insights to Safety Outcomes.*
200. CRT2010, February 23, 2010, Washington, DC. *DES (R)evolution. 'Next Generation' DES: Evidence, Impact and Unmet Needs.*
201. American College of Cardiology Scientific Sessions, March 15, 2010, Atlanta, GA. *Meet the Experts: Antegrade Technique in Chronic Total Occlusion Revascularization.*
202. *DES and Dual Antiplatelet Therapy: Current and Future Perspectives.* [www.theheart.org](http://www.theheart.org), April 20, 2010.
203. China Interventional Therapeutics, Beijing, China, April 1, 2010. FDA/SFDA Clinical Trials Workshop. *A Practical Approach to Investigator-Initiated Trial Design and Performance.*
204. China Interventional Therapeutics, Beijing, China, April 2, 2010. *Update in Endovascular Therapies for Lower Limb Disease.*

205. China Interventional Therapeutics, Beijing, China, April 2, 2010. *Defining (and Redefining) the 'Optimal' Duration of Dual Antiplatelet Therapy Following DES Revascularization.*
206. Concepts in Contemporary Cardiovascular Medicine, April 10, 2010, Houston, TX. *DES (R)evolution: Development of Bioabsorbable Polymers and Stents in Interventional Cardiology.*
207. United States Food and Drug Administration, April 13, 2010, Washington, DC. *Lessons Learned From Drug-Eluting Stents in Clinical Decision Making and Trial Design.*
208. Emory Practical Intervention Course (EPIC), April 22, 2010, Atlanta, GA. *Percutaneous Revascularization for Unprotected Left Main Disease: Advancing New Standards of Care.*
209. Angioplasty Summit, April 27, 2010, Seoul, Korea. *Prasugrel: Studies in Risk, Benefit and the Evolution of Individualized Medicine.*
210. Angioplasty Summit, April 29, 2010, Seoul, Korea. *Selected Key Clinical Trials in Interventional Cardiology 2010.*
211. Angioplasty Summit, April 29, 2010, Seoul, Korea. *Prasugrel: Outstanding Challenges with Antiplatelet Therapy: Practicing the Art of Medicine When Science May Not Exist.*
212. EuroPCR 2010, June 28, 2010, Paris, France. *Case Examples in Complex Disease.*
213. *PCI in the Complex Patient.* [www.theheart.org](http://www.theheart.org), June 29, 2010.
214. Duke Transradial Course, July 15, 2010, Durham, NC. *Guide Catheter Selection for Transradial Percutaneous Coronary Intervention.*
215. 2<sup>nd</sup> Transradial Catheterization Therapeutics, China Heart Congress/International Heart Forum 2010, August 13, 2010, Beijing, China. *Evidence Basis for Transradial Coronary Intervention.*
216. Transcatheter Therapeutics (TCT) 2010, September 22, 2010, Washington, DC. *Fundamental Responsibilities and Roles of a Principal Investigator.*
217. Transcatheter Therapeutics (TCT) 2010, September 22, 2010, Washington, DC. *DAPT Duration Following DES Revascularization: Practicing the Art of Medicine When the Science May Not Exist.*
218. Transcatheter Therapeutics (TCT) 2010, September 22, 2010, Washington, DC. *Planning a Strategy Based on the Angiogram: Fundamentals of CTO Revascularization.*
219. Transcatheter Therapeutics (TCT) 2010, September 23, 2010, Washington, DC. *Technical Considerations in CTO Revascularization: Nurse and Cath Lab Technician Symposium.*
220. Transcatheter Therapeutics (TCT) 2010, September 23, 2010, Washington, DC. *Transradial Vascular Access. Cost and Patient-related Quality of Life: Evidence Basis and Opportunity.*
221. Transcatheter Therapeutics (TCT) 2010, September 24, 2010, Washington, DC. *Clinical Considerations for CTO Revascularization: Revisiting Patient Selection.*

222. Transcatheter Therapeutics (TCT) 2010, September 25, 2010, Washington, DC. *The EXCEL Trial and Unprotected Left Main Revascularization: Lessons Learned from SYNTAX*.
223. Transcatheter Therapeutics (TCT) 2010, September 25, 2010, Washington, DC. *New DES Technology: Evidence, Impact and Unmet Needs*.
224. Innovations in Intervention. [www.theheart.org](http://www.theheart.org), September 24, 2010.
225. Transradial Intervention: Dispelling Myths and Discussing Unresolved Issues in Transradial versus Tranfemoral Catheterization. [www.theheart.org](http://www.theheart.org), September 24, 2010.
226. Napa Interventional Cardiology Course, October 8, 2010, Napa, California. *Next Generation Drug-Eluting Stents*.
227. Napa Interventional Cardiology Course, October 8, 2010, Napa, California. *Percutaneous Revascularization for Unprotected Left Main Disease: Are We Ready for a New Standard?*
228. 21<sup>st</sup> Annual Scripps Interventional Cardiology Course, October 13, 2010, La Jolla, California. *Key Clinical Trials for 2010: High Impact Trials That Influence Clinical Decision-Making*.
229. 21<sup>st</sup> Annual Scripps Interventional Cardiology Course, October 13, 2010, La Jolla, California. *Fundamentals of Radial Artery Access: From Stick to Stich*.
230. 21<sup>st</sup> Annual Scripps Interventional Cardiology Course, October 15, 2010, La Jolla, California. *Retrograde Approach to Chronic Total Occlusion Revascularization: Step by Step*.
231. 21<sup>st</sup> Annual Scripps Interventional Cardiology Course, October 13, 2010, La Jolla, California. *Impella 2.5 Hemodynamic Assist Technology: Overview of Technology and Device Performance*.
232. 21<sup>st</sup> Annual Scripps Interventional Cardiology Course, October 13, 2010, La Jolla, California. *Fractional Flow Reserve Measured in Multivessel Disease: Measuring Up to a New Standard?*
233. American Heart Association Scientific Sessions, November 13, 2010, Chicago, IL. *In Search of the 'Best' Drug-Eluting Stent: Evidence, Impact and Unmet Needs from Comparative Trials*.
234. Transradial Interventional Program, January 15, 2011, Philadelphia, PA. *Transradial and Transfemoral Vascular Closure: Is There a Clinically Meaningful Difference?*
235. 8<sup>th</sup> Annual Transcatheter Therapeutics Left Main and CTO Summit, February 15, 2011, New York, New York. *Unprotected Left Main Percutaneous Revascularization in Acute Myocardial Infarction*.
236. 8<sup>th</sup> Annual Transcatheter Therapeutics Left Main and CTO Summit, February 15, 2011, New York, New York. *Clinical Trials and Outcomes with Drug-Eluting Stents in Chronic Total Occlusion Revascularization: Redefining and Refining Standards of Treatment*.
237. Cardiovascular Revascularization Therapies, February 27, 2011, Washington, DC. *Drug-Eluting Stents for Chronic Total Occlusion Revascularization*.

238. Cardiovascular Revascularization Therapies, February 28, 2011, Washington, DC. *Dual Antiplatelet Therapy: 6 Months, 12 months, 3 years? A 'Rational' Discussion for a Patient Focused Approach.*
239. Cardiovascular Revascularization Therapies, February 28, 2011, Washington, DC. *Drug-Eluting Stents Revascularization for Erectile Dysfunction.*
240. Cardiovascular Revascularization Therapies, February 28, 2011, Washington, DC. *VANTAGE 1: First in Human Evaluation of the Cinatra Corolimus-Eluting Stent System.*
241. China Interventional Therapeutics, March 17, 2011, Beijing, China. *In Search of the 'Best' Drug-Eluting Stent: Evidence, Impact and Unmet Needs from Contemporary Trials.*
242. China Interventional Therapeutics, March 17, 2011, Beijing, China. *ENDEAVOR and RESOLUTE DES Programs: From Clinical Trials to Clinical Practice.*
243. China Interventional Therapeutics, March 17, 2011, Beijing, China. *An Evidence-Based Rationale for Transradial Percutaneous Revascularization.*
244. China Interventional Therapeutics, March 17, 2011, Beijing, China. *Opportunities for Intervention: Emerging Technology and Indications for Treatment of Peripheral Arterial Disease*
245. American College of Cardiology Scientific Sessions and I2 Summit, April 2, 2011, New Orleans, LA. *Unprotected Left Main Revascularization. Are We Ready for a New Standard?*
246. American College of Cardiology Scientific Sessions and I2 Summit, April 2, 2011, New Orleans, LA. *DILEMMA: Decisions In Unprotected Left Main Management.*
247. American College of Cardiology Scientific Sessions and I2 Summit, April 3, 2011, New Orleans, LA. *Evidence Basis for Unprotected Left Main Percutaneous Revascularization.*
248. American College of Cardiology Scientific Sessions and I2 Summit, April 4, 2011, New Orleans, LA. *Emerging Indications for Endovascular Intervention: Erectile Dysfunction.*
249. *The Cardiology Show: American College of Cardiology Scientific Sessions and I2 Summit*, April 5, 2011, [www.theheart.org](http://www.theheart.org).
250. National Cardiovascular Controversies, April 14, 2011, Lake Oconee, Georgia. *Complex Coronary Percutaneous Revascularization: Advancing Standards in Comparison with Surgery.*
251. National Cardiovascular Controversies, April 14, 2011, Lake Oconee, Georgia. *PCI for Multivessel Disease: A Practical Approach to How the SYNTAX Score Influences Clinical Decision-Making.*
252. Angioplasty Summit TCT Asia Pacific, April 27, 2011, Seoul, Korea. *Sirolimus-Eluting Stents Revisited: Unexpected Results and Clinical Implications from BASKET PROVE, SORT OUT IV, EXCELLENT and ISAR TEST 4.*
253. Angioplasty Summit TCT Asia Pacific, April 27, 2011, Seoul, Korea. *Current and Future Stent Designs for Drug-Eluting Stents.*
254. Angioplasty Summit TCT Asia Pacific, April 28, 2011, Seoul, Korea. *A Global Perspective of Catheter-Based Therapies.*

255. Angioplasty Summit TCT Asia Pacific, April 28, 2011, Seoul, Korea. *Platelet Function Testing and Outcomes.*
256. Angioplasty Summit TCT Asia Pacific, April 28, 2011, Seoul, Korea. *The Science of Future Workhorse Drug-Eluting Stents.*
257. Angioplasty Summit TCT Asia Pacific, April 29, 2011, Seoul, Korea. *Complex Coronary Intervention: Challenges of Antegrade Chronic Total Occlusion Revascularization.*
258. Hong Kong Cardiology of Cardiology Annual Scientific Sessions, April 30, 2011, Hong Kong. *Unmet Needs in Cardiovascular Medicine: Future Directions for Interventional Cardiology.*
259. Hong Kong Cardiology of Cardiology Annual Scientific Sessions, April 30, 2011, Hong Kong. *Making Complex Simple: Advances in DES Technology and Trial Design.*
260. Society for Coronary Angiography and Interventions (SCAI) 2011 Annual Sessions, May 4, 2011, Baltimore, MD. *New Frontiers in Cardiovascular Medicine: Future of Drug-Eluting Stents.*
261. Society for Coronary Angiography and Interventions (SCAI) 2011 Annual Sessions, May 4, 2011, Baltimore, MD. *Percutaneous Revascularization for Unprotected Left Main Disease: Evidence Basis.*
262. *The Bob Harrington Show: Occluded Artery Trial and Revascularization of Total Occlusions.* [www.theheart.org](http://www.theheart.org), July 22, 2011.
263. Complex Interventional Cardiovascular Therapy 2011, July 30, 2011, San Francisco, CA. *Percutaneous Revascularization for Erectile Dysfunction: Evidence, Case-Based Demonstration and Future Directions.*
264. China Heart Congress 2011, August 13, 2011, Beijing, China. *Evidence Basis For Transradial Percutaneous Coronary Intervention: Contemporary Evidence and Opportunities for Advancement.*
265. 22<sup>nd</sup> Annual Scripps Clinic Coronary Interventions, September 21, 2011, San Diego, CA. *Impella 2.5 Hemodynamic Assist Technology: Technology Overview, Utilization Technique and Expanding Indications.*
266. 22<sup>nd</sup> Annual Scripps Clinic Coronary Interventions, September 22, 2011, San Diego, CA. *Key Clinical Trials: Impact Trials that Influence Clinical Practice.*
267. 22<sup>nd</sup> Annual Scripps Clinic Coronary Interventions, September 22, 2011, San Diego, CA. *The Inverse of Can't: Complex Transradial Intervention.*
268. 22<sup>nd</sup> Annual Scripps Clinic Coronary Interventions, September 23, 2011, San Diego, CA. *Antegrade Chronic Total Occlusion Revascularization.*
269. International Technology Exchange, October 6, 2011, Sydney, Australia. *An International Perspective on Coronary Revascularization: Evidence, Impact and Unmet Needs.*
270. International Technology Exchange, October 6, 2011, Sydney, Australia. *DES Revolution, Steps Forward or Sideways?*
271. Duke Advanced Course in Transradial Angiography and Intervention, October 20-12, 2011, Durham, NC. *The Inverse of Can't: Transradial Bifurcation and Chronic Total Occlusion Revascularization.*



272. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Renal Denervation and the SYMPPLICITY HTN 3 Trial.
273. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. ENDEAVOR IV: 5-Year Final Outcomes.
274. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Endeavor Zotarolimus-Eluting Stent Program: From Clinical Trials to Clinical Practice.
275. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Self-Assessment Course, Complex Lesions: Bifurcations and Chronic Total Occlusions.
276. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Industry Sponsored Research: Challenges and Opportunities.
277. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Left Main In-Stent Restenosis: A Cautionary Tale.
278. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Revascularization Strategies for Left Main and Multivessel Coronary Disease: A Practical Approach Amidst the Complexities of Clinical Decision-Making.
279. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. Coronary Stent Fracture. Does it Still Happen? Do we care?
280. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. CTO Toolbox and Technique: Microcatheters, Support Catheters and Stents.
281. 2011 Transcatheter Therapeutics Scientific Sessions, November 7-11, 2011, San Francisco, CA. *Live Case Demonstrations from Piedmont Heart Institute, Atlanta, GA.*
282. Complex Lesion Case Series: Fractional Flow Reserve and Multivessel Coronary Disease. [www.theheart.org](http://www.theheart.org), November 8, 2011.
283. Making Same Day Discharge a Reality. [www.theheart.org](http://www.theheart.org), November 9, 2011.
284. 2011 American Heart Association Scientific Sessions, November 15, 2011, Orlando, FL. Renal Denervation for Resistant Hypertension: Rationale and Design of the SYMPPLICITY III Trial.
285. 4<sup>th</sup> Annual Puerto Rican Society of Interventional Cardiology Meeting, December 4, 2011, San Juan, PR. *The Future of Interventional Cardiology: Evidence, Impact and Unmet Needs.*
286. 4<sup>th</sup> Annual Puerto Rican Society of Interventional Cardiology Meeting, December 4, 2011, San Juan, PR. *Contemporary Chronic Total Occlusion Revascularization.*
287. Society of Thoracic Surgeons Annual Scientific Sessions, January 30, 2012, Fort Lauderdale, FL. *Advances in Drug-Eluting Coronary Stents: Opportunities for Evidence and Evolution.*

288. Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Clinical Trials and Outcomes with Drug-Eluting Stents in Chronic Total Occlusion Revascularization*.
289. Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Catheter-Based Renal Denervation for Resistant Hypertension: Therapeutic Options for Those Previously Without Alternative*.
290. Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Advanced Generation Drug-Eluting Stents: Evidence, Impact and Unmet Needs From Comparative Trials*.
291. Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Coronary Perforation: Management Issues*.
292. Cardiovascular Research Technologies (CRT) 2012, February 6, 2012, Washington, DC. *Advanced Methods for Guiding Catheter Support: Expecting and Overcoming Challenges in Chronic Total Occlusion Revascularization*.
293. Scottsdale Interventional Forum 2012, February 17, 2012, Scottsdale, AZ. *Hemodynamic Support in Acute Myocardial Infarction*.
294. Scottsdale Interventional Forum 2012, February 17, 2012, Scottsdale, AZ. *Chronic Total Occlusion Revascularization: Strategy and Technique*.
295. Scottsdale Interventional Forum 2012, February 17, 2012, Scottsdale, AZ. *Intravascular Ultrasound Imaging in Left Main Percutaneous Revascularization: Measuring Up to New Standards*.
296. Complex Coronary Interventions: 10<sup>th</sup> Annual Left Main and CTO Summit, February 23, 2012, New York, NY. *Left Main Percutaneous Revascularization: The Year in Review and What is to Come*.
297. Complex Coronary Interventions: 10<sup>th</sup> Annual Left Main and CTO Summit, February 23, 2012, New York, NY. *1 versus 2 Stent Revascularization Strategies for Left Main Disease: A Practical and Evidence Oriented Approach to Clinical Decision-Making*.
298. Complex Coronary Interventions: 10<sup>th</sup> Annual Left Main and CTO Summit, February 24, 2012, New York, NY. *Angiographic and Clinical Surveillance Following Left Main Percutaneous Revascularization: Is It Worth Taking a Look?*
299. Complex Coronary Interventions: 10<sup>th</sup> Annual Left Main and CTO Summit, February 25, 2012, New York, NY. *Live Case Demonstrations from Piedmont Heart Institute, Atlanta, GA*.
300. Interventional Cardiology 2012: 27<sup>th</sup> Annual International Symposium, March 4-9, 2012, Snowmass, Colorado. *Catheter-based Renal Denervation: Design and Rationale of the SYMPLCITY HTN-3 Trial*.
301. Interventional Cardiology 2012: 27<sup>th</sup> Annual International Symposium, March 4-9, 2012, Snowmass, Colorado. *Emerging Indications for Endovascular Therapies: Erectile Dysfunction*.
302. China Interventional Therapeutics, February 2012, Beijing, China. *Percutaneous Left Main Revascularization: A Perspective from The United States*.
303. China Interventional Therapeutics, February 2012, Beijing, China. *Endeavor and Resolute Zotarolimus-Eluting Stent Programs*.

304. China Interventional Therapeutics, February 2012, Beijing, China. *Resolute Drug Eluting Stent Program.*
305. American College of Cardiology Scientific Sessions, March 25, 2012, Chicago, IL. *The Inverse of Can't and Won't: An Evidence- and Practice-Based Rationale for Transradial Coronary Intervention.*
306. American College of Cardiology Scientific Sessions, March 25, 2012, Chicago, IL. *Revascularization Strategies for Left Main and Multivessel Disease: A Practical Approach Amidst the Complexities of Clinical Decision Making.*
307. American College of Cardiology Scientific Sessions, March 25, 2012, Chicago, IL. *Complex Coronary Revascularization: A Year in Review.*
308. American College of Cardiology Scientific Sessions, March 24, 2012, Chicago, IL. *Percutaneous Left Main Revascularization: Evidence for Clinical Decision Making and Guidelines.*
309. American College of Cardiology Scientific Sessions, March 24, 2012, Chicago, IL. *Percutaneous Left Main Revascularization: Evolution of Method and Evidence.*
310. Atlanta Academy of Institutional Pharmacy, April 19, 2012, Atlanta, GA. *The Art and Science of Clinical Decision Making for Antiplatelet Therapy: Studies in Risk, Benefit and the Evolution of Individualized Medicine.*
311. 18<sup>th</sup> Annual Interventional Cardiology Fellows Course, April 21, 2012, Miami, FL. *The Endeavor and Resolute Zotarolimus-Eluting Stent Programs.*
312. 18<sup>th</sup> Annual Interventional Cardiology Fellows Course, April 22, 2012, Miami, FL. *Chronic Total Occlusion Revascularization.*
313. Angioplasty Summit/ TCT Asia, April 26, 2012, Seoul, Korea. *What is the final goal of transcatheter renal denervation?*
314. Angioplasty Summit/ TCT Asia, April 26, 2012, Seoul, Korea. *Catheter-based renal denervation for hypertension and other areas of research.*
315. Angioplasty Summit/ TCT Asia, April 26, 2012, Seoul, Korea. *Application of renal denervation to treatment of chronic heart failure.*
316. Piedmont Heart Institute, Cardiology Grand Rounds, May 9, 2012. *Catheter-based renal denervation for uncontrolled hypertension.*
317. Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Unprotected left main revascularization: evolution of science and method.*
318. Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Longitudinal stent distortion: the intersection of design and technique.*
319. Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Catheter-based renal denervation for resistant hypertension: therapeutic alternatives for those previously without option.*
320. Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Left main percutaneous revascularization: an interventional perspective of advances in science and method.*
321. Society of Coronary Angiography and Interventions (SCAI), May 10-12, 2012, Las Vegas, NV. *Economic outcomes associated with complex percutaneous revascularization: the cost of chronic total occlusion revascularization.*



322. Society of Coronary Angiography and Interventions (SCAI) Women in Innovations (WIN) Program, September 24, 2012, Washington, DC. *ENDEAVOR zotarolimus-eluting stent program angiographic and clinical outcomes for women with symptomatic coronary artery disease.*
323. Evolution of Stent Design and Optimizing Percutaneous Coronary Intervention, [www.theheart.org](http://www.theheart.org), October 22, 2012.
324. From Good to Great: Improving the Economics of PCI Outcomes, [www.theheart.org](http://www.theheart.org), October 23, 2012.
325. Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Industry-sponsored versus investigator-initiated research: similarities, differences and pathways to success.*
326. Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Left main bifurcation stenting: highlights from the past 12 months.*
327. Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Rationale and data for different DAPT durations: from 3 months to 30 months or longer.*
328. Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *15<sup>th</sup> annual interventional cardiology board review course: bifurcations and chronic total occlusions.*
329. Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *SYMPPLICITY HTN-3 trial design and current status.*
330. Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *DESSOLVE II: a prospective, randomized trial of biodegradable polymer-based sirolimus-eluting stent versus a zotarolimus-eluting stent.*
331. Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Live case transmissions from Piedmont Heart, Atlanta, GA.*
332. Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *FDA Town Hall meeting: An objective performance criterion model for “standard” drug-eluting stent approval.*
333. Transcatheter Therapeutics (TCT) Scientific Sessions, October 22-26, 2012, Miami, FL. *Chronic total occlusion guidewire design and selection: antegrade and retrograde approaches.*
334. 8<sup>th</sup> Transradial Intervention Course, November 3, 2012, Ahmedabad, India. *Transradial unprotected left main coronary revascularization.*
335. Piedmont Healthcare Internal Medicine Grand Rounds, November 7, 2012, Atlanta, GA. *Renal Denervation Therapy for Resistant Hypertension and Sympathetic-mediated Disease Conditions.*
336. 7<sup>th</sup> Annual International Technology Exchange, November 16, 2012, Sydney, Australia. *Realizing the Real Benefit of PCI: Applying Effective Therapy to Identify Those Who Benefit Most.*
337. Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Chronic Total Occlusion Revascularization 2013: Evolution of Strategy and Technique.*

338. Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Algorithm and Tools for the Uncrossable Chronic Total Occlusion*.
339. Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Coronary perforation in Chronic Total Occlusion Revascularization: Management Issues*.
340. Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Controlled Antegrade and Retrograde Tracking with Snaring of Retrograde Guidewire*.
341. Society of Coronary Angiography and Interventions Chronic Total Occlusion Regional Training Program, January 19, 2013, Phoenix, AZ. *Percutaneous Chronic Total Occlusion Revascularization: Modeling a High Volume, Clinically Successful Program*.
342. ISET 2013, January 21, 2013, Miami, FL. *Catheter-based Renal Denervation for Resistant Hypertension. Therapeutic Options for Those Previously Without Alternative*.
343. ISET 2013, January 21, 2013, Miami, FL. *Catheter-based Renal Denervation for Resistant Hypertension. Evolution of Evidence and Technology*.
344. Marquis Lecture, Scottsdale Interventional Forum, February 14, 2013. *Left Main Revascularization: An Interventional Perspective on Advances in Science and Method*.
345. 10<sup>th</sup> Annual Left Main and Chronic Total Occlusion Summit, February 23, 2013, New York, New York. *Live Case Operator, Piedmont Heart Institute*.
346. CRT 2013, February 26, 2013, Washington, DC. *PCI Appropriateness Criteria. We Can Do Better*.
347. CRT 2013, February 26, 2013, Washington, DC. *Ventricular Assist Devices and Regulatory Challenges: An Academic View*.
348. CRT 2013, February 26, 2013, Washington, DC. *Clinical Trial Design Considerations for Moderate and Resistant Hypertension*.
349. CRT 2013, February 26, 2013, Washington, DC. *Clinical Trial Design Considerations for Moderate and Resistant Hypertension*.
350. CRT 2013, February 26, 2013, Washington, DC. *Catheter-based Renal Denervation with the SYMPPLICITY System Provides Safe and Durable Blood Pressure Reduction out to Three Years*.
351. American College of Cardiology, March 9, 2013, San Francisco, CA. *Left Main Revascularization: Perspective on Advances in Method, Outcome and Clinical Decision Making*.
352. American College of Cardiology, March 10, 2013, San Francisco, CA. *Debate: DES Revolution: Bioresorbable Stents Will Only Maintain a Niche Indication*.
353. American College of Cardiology, March 9, 2013, San Francisco, CA. *Chronic Total Occlusion Revascularization: Remove CTOs from Appropriateness Use Criteria*.

354. American College of Cardiology, March 9, 2013, San Francisco, CA. *CTO Percutaneous Revascularization: All the Reasons You Should Do It, and There Has Never Been a Better Time to Learn.*
355. American College of Cardiology, March 9, 2013, San Francisco, CA. *Algorithm and Tools for The Uncrossable CTO.*
356. American College of Cardiology, March 9, 2013, San Francisco, CA. *Post Acute Myocardial Infarction Risk for Sudden Death: Incidence, Predictors and Strategies to Reduce Risk.*
357. China Interventional Therapeutics, March 21, 2013, Beijing, China. *Renal Denervation Therapy with the SYMPPLICITY System and Clinical Trial Program.*
358. China Interventional Therapeutics, March 21, 2013, Beijing, China. *Chronic Total Occlusion Revascularization in 2013: Evolution of Strategy and Technique.*
359. China Interventional Therapeutics, March 22, 2013, Beijing, China. *Chronic Total Occlusion Revascularization in 2013: What You Need to Know.*
360. China Interventional Therapeutics, March 22, 2013, Beijing, China. *ACC at CIT: Dual Antiplatelet Therapy and Drug Eluting Stents.*
361. China Interventional Therapeutics, March 22, 2013, Beijing, China. *Complex Left Main and Multivessel Disease. Live case operator.*
362. Japanese Circulation Society, March 28, 2013, Tokyo, Japan. *Enrollment Strategies and Technique for Renal Denervation Therapy.*
363. 19<sup>th</sup> Annual Interventional Fellows Course, April 16, 2013, San Jose, CA. *Overview of Chronic Total Occlusion Revascularization.*
364. Piedmont Cardiology Napa Valley 2013, April 18, 2013, Napa, CA. *Unprotected Left Main and Multivessel Coronary Revascularization Strategies.*
365. Piedmont Cardiology Napa Valley 2013, April 18, 2013, Napa, CA. *Renal Denervation Therapy for Resistant Hypertension.*
366. Piedmont Cardiology Napa Valley 2013, April 18, 2013, Napa, CA. *Advances in Lower Limb Revascularization for Intermittent Claudication and Critical Limb Ischemia.*
367. SCAI 2013, May 9, 2013, Orlando, FL. *Left Main Coronary Revascularization: Perspective on Method, Outcome and Clinical Decision Making.*
368. EuroPCR 2013, May 21, 2013, Paris, France. *Stent Conformation and Impact on Clinical Outcome: Intersection of Design and Technique.*
369. EuroPCR 2013, May 21, 2013, Paris, France. *SYMPPLICITY Trial Clinical Program Overview.*
370. www.theheart.org. May 21, 2013. *Dual Antiplatelet Therapy Following Percutaneous Revascularization: An International Perspective.*
371. www.theheart.org. May 21, 2013. *Renal Denervation Therapy for Resistant Hypertension: An International Perspective.*
372. NYC TRAC Transradial Course, June 28, 2013, New York. *Why the Radial Now in the United States? Clinical, Economic and Quality of Life Incentives.*
373. SIRIUS Radio, July 3, 2013. *Heart to Heart with Dr. Fred Feit.*

374. 15<sup>th</sup> Annual Cardiovascular Symposium, September 7, 2013, San Bernadino, CA. *Physiologic Rationale for Interventional Therapies in Hypertension. Renal Artery Denervation: The Novel Therapy for the Resistant Hypertension.*
375. 24<sup>th</sup> Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Transradial Intervention and Guide Catheter Selection: Procedure with a Purpose.*
376. 24<sup>th</sup> Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Key Clinical Trials 2013: Impact Trials that Influence Clinical Practice.*
377. 24<sup>th</sup> Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Stent Structure and Impact on Procedural and Clinical Outcomes.*
378. 24<sup>th</sup> Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Percutaneous CTO Revascularization: Modeling a High Volume, Clinically Successful Program.*
379. 24<sup>th</sup> Annual Scripps Cardiovascular Interventions, October 5, 2013, La Jolla, CA. *Chronic Total Occlusion Revascularization 2013: Evolution of Strategy and Technique.*
380. Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *Device and Clinical Trial Update: SYMPPLICITY and SPYRAL for Renal Denervation.*
381. Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *Moderate Resistant Hypertension: A New Indication for Renal Artery Denervation?*
382. Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *The Evolution from Endeavor to Resolute: Stent Design Considerations and Results.*
383. Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *The Masters' Solutions: Complex Left Main Trifurcation Disease.*
384. Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *First-in-human experience with a novel high-flow percutaneous heart pump.*
385. Transcatheter Therapeutics (TCT) Scientific Sessions, October 27-30, 2013, San Francisco, CA. *Live case operator, chronic total occlusion cases from Piedmont Hospital, Atlanta, GA.*
386. American Heart Association Scientific Sessions, November 18, 2013, Dallas, TX. *Complex Transradial Percutaneous Coronary Revascularization.*
387. American Heart Association Scientific Sessions, November 18, 2013, Dallas, TX. *Chronic Total Occlusion Revascularization: Advances in Strategy and Technique.*
388. 11<sup>th</sup> Annual Left Main and Chronic Total Occlusion Summit, February 2013, New York, New York. *Left Main Trifurcation Disease.*
389. CRT 2014, February 2014, Washington, DC. *Renal Denervation Trial Considerations for Moderate Hypertension.*

390. China Interventional Therapeutics 2014, March 2014, Shanghai, China. *Back to the Basics for Bifurcations: Angiography Alone is All that is Needed.*
391. China Interventional Therapeutics 2014, March 2014, Shanghai, China. *Perspectives on Renal Denervation: Opportunity or End, What's Next.*
392. China Interventional Therapeutics 2014, March 2014, Shanghai, China. *Evolution from Endeavor to Resolute: Stent Design Considerations and Results.*
393. American College of Cardiology Scientific Sessions, March 2014. *Pharmacodynamic considerations and clinical impact of dual antiplatelet therapy interruption after Resolute zotarolimus-eluting stent implantation.*
394. American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *Fellows' Course: Bifurcation, Ostial and Left Main Disease: Perspectives on Advances in Method, Outcome and Clinical Decision Making.*
395. American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *Transradial Primary PCI: Accents, Access, Evidence and Good Common Sense.*
396. American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *Left Main Percutaneous Revascularization.*
397. American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *Safety and Effectiveness of Xience Drug-Eluting Stents in Chronic Total Occlusion Revascularization: Results from the EXPERT CTO Multicenter Clinical Trial.*
398. American College of Cardiology Scientific Sessions, March 2014, Washington, DC. *SYMPPLICITY HTN-3: An In-depth Discussion Regarding Trial Results and the Future of Renal Denervation, [www.tctmd.com](http://www.tctmd.com)*
399. TCTAP 19<sup>th</sup> Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Non-Hypertension Indications for Renal Denervation Therapy.*
400. TCTAP 19<sup>th</sup> Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Left Main Revascularization and the EXCEL Clinical Trial.*
401. TCTAP 19<sup>th</sup> Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Principal Results from the SYMPPLICITY HTN 3 Trial and Global Symplcity Registry.*
402. TCTAP 19<sup>th</sup> Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Live case operator, unprotected left main disease.*
403. TCTAP 19<sup>th</sup> Cardiovascular Summit, April 24-25, 2014, Seoul, Korea. *Renal Denervation Beyond SYMPPLICITY HTN 3: Next Steps.*
404. EuroPCR, May 21, 2014, Paris, France. *Sudden cardiac death in post-acute myocardial infarction and post-revascularization patients. Who is at risk?*
405. EuroPCR, May 22, 2014, Paris, France. *Hotline Session: SYMPPLICITY HTN3: Subgroup Analyses of Predictors of Blood Pressure Response*
406. *Navigating the Maze of SYMPPLICITY HTN 3.* May 21, 2014, Paris, France. [www.theheart.org](http://www.theheart.org).
407. American Society of Hypertension/ Food and Drug Administration Think Tank Meeting. *Procedural considerations for renal denervation.* June 26, 2014. Washington, DC.
408. *PCI Master Class: Complex PCI -- Deconstructing the Tools of the Trade.* July 31, 2014. [www.theheart.org](http://www.theheart.org).

409. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Dual Antiplatelet Therapy Following Percutaneous Revascularization: A Case Study.*
410. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Transradial Primary Percutaneous Intervention: Access and Evidence.*
411. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Perspectives on Same Day Discharge: Once Nice to Have, Now Essential.*
412. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Left Main Anatomy and Consequences.*
413. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Renal Denervation, Not So Simple: Still Afloat, Not Dead in the Water.*
414. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *HeartMate Percutaneous Heart Pump: A Novel High Flow Circulatory Support Catheter.*
415. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Renal Denervation for Hypertension: Overview of Clinical Trials and Next Steps.*
416. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Primary Endpoint Results from the PROMUS Element Plus US Post-Approval Study (PE-Plus PAS): 1-Year Outcomes in Real-World Patients Treated With a Thin-Strut, Platinum-Chromium, Everolimus-Eluting Stent.*
417. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *Bifurcation PCI with Physiologic Guidance: Crossroads for Clinical Decision Making.*
418. Transcatheter Therapeutics Scientific Sessions (TCT) 2014, Washington, DC, October 2014. *SYMPPLICITY HTN 3 Trial: Mechanistic Insights to Blood Pressure Response.*
419. SCAI Transradial Interventional Program (TRIP), Atlanta, GA, January 24, 2015. *From the Wrist to the Coronaries: Overcoming Challenges of Catheter Advancement and Positioning.*
420. SCAI Transradial Interventional Program (TRIP), Atlanta, GA, January 24, 2015. *Balancing Costs with Quality in PCI.*
421. SCAI Transradial Interventional Program (TRIP), Atlanta, GA, January 24, 2015. *Complications with Transradial Catheterization.*
422. CRT2015, Washington, DC, February 22-24, 2015. *SYMPPLICITY HTN 3 Trial: Subgroup Analyses.*
423. CRT2015, Washington, DC, February 22-24, 2015. *Renal Denervation for Moderate Hypertension: The Spyral Clinical Trial Program.*
424. CRT2015, Washington, DC, February 22-24, 2015. *Uncommon Complications in Chronic Total Occlusion Percutaneous Coronary Intervention and Management.*

425. Chronic Total Occlusion Summit, New York, February 25, 2015. *Contemporary Outcomes with Chronic Total Occlusion Revascularization*.
426. Chronic Total Occlusion Summit, New York, February 25, 2015. *Chronic Total Occlusion Revascularization 2015: Need for Advanced Training and Technique*.
427. American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *Left Main Anatomy and Consequences*.
428. American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *The Heart Team Approach: A 'Disruptive' Strategy*.
429. American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *Evolution of DES Trials: Studies with Novel Bioresorbable and Permanent Polymer DES*.
430. American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *Post AMI Risk for Sudden Cardiac Death: Incidence, Predictors and Strategies to Reduce Risk*.
431. American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *DAPT Duration in Contemporary PCI: Practicing the Art of Medicine with Limited Science*.
432. American College of Cardiology Scientific Sessions, San Diego, CA, March 13-16, 2015. *Fellows' Bootcamp: Overcoming Challenges in Transradial Cardiac Catheterization*.
433. China Interventional Therapeutics, Beijing, March 20-21, 2015. *Live case operator*.
434. China Interventional Therapeutics, Beijing, March 20-21, 2015. *Updates from SYMPPLICITY HTN-3: What We Know and What We Have Learned*.
435. China Interventional Therapeutics, Beijing, March 20-21, 2015. *Advanced Training and Specialization for CTO Practitioners*.
436. China Interventional Therapeutics, Beijing, March 20-21, 2015. *Debate: Prolonged DAPT Is Mandatory after Stenting*.
437. ACC 2015 For Interventional Cardiology: TOTAL, MATRIX, DANAMI. March 26, 2015. [www.medscape.com](http://www.medscape.com).
438. Latin American Technology and Therapy Exchange. *Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention 2015*. April 9, 2015, Montevideo, Uruguay.
439. Latin American Technology and Therapy Exchange. *Renal Denervation: Next Steps*. April 9, 2015, Montevideo, Uruguay.
440. Latin American Technology and Therapy Exchange. *Chronic Total Occlusion Strategy and Method*. April 10, 2015, Montevideo, Uruguay.
441. Latin American Technology and Therapy Exchange. *Bioresorbable Scaffolding: Debate*. April 9, 2015, Montevideo, Uruguay.
442. EuroPCR 2015 Scientific Sessions. *Renal Denervation and Evolution of Science and Technique: Mechanistic Insights to Blood Pressure Response, Subgroup Analyses and Future Directions*. May 20, 2015, Paris, France.
443. EuroPCR 2015 Scientific Sessions. *Spyral HTN: Considerations for Trial Design in Moderate Hypertension*. May 20, 2015, Paris, France.

- 444. EuroPCR 2015 Scientific Sessions. *Renal Denervation, Back to the Future*. May 20, 2015, [www.medscape.com](http://www.medscape.com)
- 445. Piedmont Napa Valley Cardiology Conference. *Completeness of Revascularization: Beneficial, Practical, Achievable?* June 5, 2015, Napa, California.
- 446. Piedmont Napa Valley Cardiology Conference. *Renal Denervation Next Steps*. June 5, 2015, Napa, California.
- 447. C3 Complex Coronary Interventions. *Antegrade Bailout Chronic Total Occlusion Coronary Intervention*. June 10, 2015, Orlando, FL.